101
|
Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing Klebsiella pneumoniae in Bulgaria. APMIS 2015; 123:887-94. [PMID: 26303718 DOI: 10.1111/apm.12433] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2015] [Accepted: 07/13/2015] [Indexed: 12/30/2022]
Abstract
A total of 36 consecutive clinical and two fecal-screening carbapenem-resistant Klebsiella pneumoniae isolates from two Bulgarian university hospitals (Varna and Pleven) were investigated. Susceptibility testing, conjugation experiments, and plasmid replicon typing were carried out. Beta-lactamases were characterized by isoelectric focusing, PCR, and sequencing. Clonal relatedness was investigated by RAPD and multilocus sequence typing (MLST). Most of the isolates demonstrated multidrug resistance profile. Amikacin and tigecycline retained good activity with susceptibility rates of 95 and 87%, respectively. The resistance rate to colistin was 63%. Six RAPD- and MLST-types were identified: the dominating MLST-type was ST15 (27 isolates), followed by ST76 (six isolates), and ST1350 (two isolates). ST101, ST258, and ST151 were detected once. All except one of the K. pneumoniae produced KPC-2, mostly in combination with CTX-M-15, while for one isolate (ST101) the enzymes OXA-48 and CTX-M-14 were found. All KPC-2-producing transconjugants revealed the presence of IncFII plasmid. The OXA-48- and CTX-M-14-producing isolate showed the presence of L/M replicon type. The dissemination of KPC-2-producing K.pneumoniae in Bulgaria is mainly due to the sustained spread of successful ST15 clone and to a lesser extent of ST76 clone. This is the first report of OXA-48 producing ST101 K. pneumoniae in Bulgaria.
Collapse
Affiliation(s)
- Rumyana Markovska
- Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria
| | - Temenuga Stoeva
- Department of Microbiology, Medical University of Varna, Varna, Bulgaria
| | | | - Lyudmila Boyanova
- Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria
| | | | - Daniela Dacheva
- Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | - Radka Kaneva
- Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | | | - Vanyo Mitev
- Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | - Ivan Mitov
- Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria
| |
Collapse
|
102
|
Shumnalieva R, Kachakova D, Monov S, Kaneva R, Kolarov Z, Rashkov R. AB0018 Altered Expression of Synovial Fluid Microrna-155 in Rheumatoid Arthritis Patients. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
103
|
Tzveova R, Dimitrova-Karamfilova A, Saraeva R, Solarova T, Naydenova G, Petrova I, Hristova N, Popov I, Nachev G, Mitev V, Kaneva R. Estimation and validation of acenocoumarol dosing algorithms in Bulgarian patients with cardiovascular diseases. Per Med 2015; 12:209-220. [PMID: 29771648 DOI: 10.2217/pme.14.80] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Aim & Methods: A total of 169 Bulgarian patients were genotyped for CYP2C9*2,*3, VKORC1-1639G>A and VKORC11173C>T. The effect of genetic and nongenetic factors on acenocoumarol dose variability was tested in a derivation cohort of patients and the obtained algorithm was validated in a test cohort. RESULTS & DISCUSSION It was found that VKORC-1639G>A (25.5%), CYP2C9*2 (7.8%), CYP2C9*3 (6.1%), age (13.6%) and diagnosis (6.0%) significantly affected acenocoumarol dose variability in the derivation cohort. These factors with additional factors, such as sex (0.1%, p = 0.76), weight (2.6%, p = 0.14) and amiodarone use (3.0%, p = 0.059) accounted for 46.5% and 23.0% of the dose variability for genetic and clinical models, respectively. CONCLUSION Based on the results of this investigation, validated clinical and pharmacogenetic algorithms for the prediction of a stable anticoagulant dose were developed, specifically designed for the Bulgarian population.
Collapse
Affiliation(s)
- Reni Tzveova
- Molecular Medicine Center, Department of Medical Chemistry & Biochemistry, Medical Faculty, Medical University - Sofia, 2 Zdrave str, Sofia 1431, Bulgaria
| | - Antoaneta Dimitrova-Karamfilova
- Department of Clinical Laboratory, University National Multi-profile Active Treatment Hospital "St. Ekaterina"- Sofia, 52A Pencho Slaveykov bul., Sofia 1431, Bulgaria
| | - Radoslava Saraeva
- Molecular Medicine Center, Department of Medical Chemistry & Biochemistry, Medical Faculty, Medical University - Sofia, 2 Zdrave str, Sofia 1431, Bulgaria
| | - Tanya Solarova
- Department of Clinical Laboratory, University National Multi-profile Active Treatment Hospital "St. Ekaterina"- Sofia, 52A Pencho Slaveykov bul., Sofia 1431, Bulgaria
| | - Galya Naydenova
- Second Department of Cardiology, University NationalMulti-profile Active Treatment Hospital "Dr. G. Stansky"- Pleven, 8A Georgi Kochev str., Pleven 5800, Bulgaria
| | - Irina Petrova
- Department of Clinical Laboratory, University National Multi-profile Active Treatment Hospital "St. Ekaterina"- Sofia, 52A Pencho Slaveykov bul., Sofia 1431, Bulgaria
| | - Nataliya Hristova
- Department of Clinical Laboratory, University National Multi-profile Active Treatment Hospital "St. Ekaterina"- Sofia, 52A Pencho Slaveykov bul., Sofia 1431, Bulgaria
| | - Ivan Popov
- Molecular Medicine Center, Department of Medical Chemistry & Biochemistry, Medical Faculty, Medical University - Sofia, 2 Zdrave str, Sofia 1431, Bulgaria
| | - Gencho Nachev
- Department of Cardiac Surgery, University National Multi-profile Active Treatment Hospital "St. Ekaterina"- Sofia, 52A Pencho Slaveykov bul., Sofia 1431, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Center, Department of Medical Chemistry & Biochemistry, Medical Faculty, Medical University - Sofia, 2 Zdrave str, Sofia 1431, Bulgaria
| | - Radka Kaneva
- Molecular Medicine Center, Department of Medical Chemistry & Biochemistry, Medical Faculty, Medical University - Sofia, 2 Zdrave str, Sofia 1431, Bulgaria
| |
Collapse
|
104
|
Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, Spurdle AB, Clements JA, Park JY, Batra J. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discov 2015; 5:368-79. [PMID: 25691096 PMCID: PMC4390388 DOI: 10.1158/2159-8290.cd-14-1057] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Accepted: 02/02/2015] [Indexed: 02/02/2023]
Abstract
UNLABELLED Prostate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identified 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3' untranslated region of genes predicted to affect miRNA binding (miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated (P<2.3×10(-5)) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specific affinity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affinity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role. SIGNIFICANCE Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk.
Collapse
Affiliation(s)
- Shane Stegeman
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia
| | - Ernest Amankwah
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
| | - Kerenaftali Klein
- Statistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Tracy A O'Mara
- Molecular Cancer Epidemiology Laboratory, Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Donghwa Kim
- Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Hui-Yi Lin
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida
| | | | - Thomas A Sellers
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
| | - Srilakshmi Srinivasan
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia
| | - Rosalind Eeles
- The Institute of Cancer Research, London, United Kingdom. Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, United Kingdom
| | - Doug Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | | | - Ali Amin Al Olama
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | - Sara Benlloch
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | | | - Graham G Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Christopher A Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California
| | - Johanna Schleutker
- Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland. Institute of Biomedical Technology/BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland
| | - Børge G Nordestgaard
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - David Neal
- Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Addenbrooke's Hospital, Cambridge; Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom
| | - Paul Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | - Kay-Tee Khaw
- Cambridge Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
| | - Janet L Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington
| | - William J Blot
- International Epidemiology Institute, Rockville, Maryland
| | | | - Christiane Maier
- Department of Urology, University Hospital Ulm, Ulm, Germany. Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Adam S Kibel
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts. Washington University, St. Louis, Missouri
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Lisa Cannon-Albright
- Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Radka Kaneva
- Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria
| | - Manuel R Teixeira
- Department of Genetics, Portuguese Oncology Institute, Porto; Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Amanda B Spurdle
- Molecular Cancer Epidemiology Laboratory, Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Judith A Clements
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia
| | - Jong Y Park
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
| |
Collapse
|
105
|
Popov TM, Goranova T, Stancheva G, Kaneva R, Dikov T, Chalakov I, Rangachev J, Konov D, Todorov S, Stoyanov O, Mitev V. Relative quantitative expression of hypoxia-inducible factor-1α, -2α and -3α, and vascular endothelial growth factor A in laryngeal carcinoma. Oncol Lett 2015; 9:2879-2885. [PMID: 26137164 DOI: 10.3892/ol.2015.3070] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Accepted: 03/05/2015] [Indexed: 01/07/2023] Open
Abstract
The aim of the present study was to determine the relative quantitative expression of hypoxia-inducible factor (HIF)-1α, -2α and -3α, and VEGF-A in laryngeal carcinoma. A total of 63 patients with carcinoma of the larynx were enrolled in the study. Total RNA was isolated from fresh, frozen normal and tumor tissues of each patient, and quantitative polymerase chain reaction was performed. HIF-1α was upregulated in the majority of patients (44 patients; 69.84%). By contrast, only 7 (11.11%) patients from the whole group displayed HIF-2α overexpression, while the HIF-3α isoform was silenced in the majority of patients (48 patients, 76.19%). A small group of 5 (7.94%) patients exhibited significant overexpression of the HIF-3α isoform. VEGF-A expression was significantly higher (P<0.05) in patients with upregulated HIF-1α (2.72±1.41 RQ) compared with patients without upregulated HIF-1α (1.86±1.46 RQ). There was a moderate positive correlation between mRNA expression levels of HIF-1α and VEGF-A (rs=0.392; P<0.005). To the best of our knowledge, this study is first to report quantitative data with regard to the expression of all three HIF isoforms in malignant neoplasms. The findings suggest the existence of specific phenotypes of HIF expression in laryngeal carcinoma, where the HIF switch is absent.
Collapse
Affiliation(s)
| | - Teodora Goranova
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Gergana Stancheva
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Radka Kaneva
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Tihomir Dikov
- Department of Pathology, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Ivan Chalakov
- Department of Ear, Nose and Throat, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Julian Rangachev
- Department of Ear, Nose and Throat, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Dimitar Konov
- Department of Ear, Nose and Throat, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Spiridon Todorov
- Department of Ear, Nose and Throat, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Orlin Stoyanov
- Department of Ear, Nose and Throat, Medical University of Sofia, Sofia 1680, Bulgaria
| | - Vanio Mitev
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia 1680, Bulgaria
| |
Collapse
|
106
|
Shumnalieva R, Kachakova D, Monov S, Kaneva R, Zl K, Rashkov R. A6.24 Does the altered expression of micro-RNA-155 and micro-146A in synovial fluid of rheumatoid arthritis patients correlate with the ultrasound scores for active synovitis? Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
107
|
Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C, Kaneva R. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 2014; 34:189-200. [PMID: 25521481 DOI: 10.1089/dna.2014.2663] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
In the current study, expression levels of let-7c, miR-30c, miR-141, and miR-375 in plasma from 59 prostate cancer (PC) patients with different clinicopathological characteristics and two groups of controls: 16 benign prostatic hyperplasia (BPH) samples and 11 young asymptomatic men (YAM) were analyzed to evaluate their diagnostic and prognostic value in comparison to prostate-specific antigen (PSA). miR-375 was significantly downregulated in 83.5% of patients compared to BPH controls and showed stronger diagnostic accuracy (area under the curve [AUC]=0.809, 95% CI: 0.697-0.922, p=0.00016) compared with PSA (AUC=0.710, 95% CI: 0.559-0.861, p=0.013). Expression levels of let-7c showed potential to distinguish PC patients from BPH controls with AUC=0.757, but the result did not reach significance. Better discriminating performance was observed when combinations of studied biomarkers were used. Sensitivity of 86.8% and specificity of 81.8% were reached when all biomarkers were combined (AUC=0.877) and YAM were used as calibrators. None of the studied microRNAs (miRNAs) showed correlation with clinicopathological characteristics. PSA levels were significantly correlated with the Gleason score, tumor stage, and lymph node metastasis with Spearman correlation coefficients: 0.612, 0.576, and 0.458. In conclusion, the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
Collapse
Affiliation(s)
- Darina Kachakova
- 1 Department of Medical Chemistry and Biochemistry, Molecular Medicine Center , Medical University-Sofia, Sofia, Bulgaria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
108
|
Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TLJ, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46:1103-9. [PMID: 25217961 PMCID: PMC4383163 DOI: 10.1038/ng.3094] [Citation(s) in RCA: 344] [Impact Index Per Article: 34.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Accepted: 08/19/2014] [Indexed: 02/02/2023]
Abstract
Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of > 10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10(-8); 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.
Collapse
Affiliation(s)
- Ali Amin Al Olama
- 1] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [2]
| | | | - Sonja I Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - David V Conti
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Fredrick Schumacher
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Ying Han
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Sara Benlloch
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Dennis J Hazelett
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Zhaoming Wang
- 1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA. [2] Cancer Genomics Research Laboratory, National Cancer Institute, Division of Cancer Epidemiology and Genetics, SAIC-Frederick, Inc., Frederick, Maryland, USA
| | | | | | - Sara Lindstrom
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
| | | | | | | | - Daniel O Stram
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Kristin Rand
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Peggy Wan
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Alex Stram
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Xin Sheng
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Loreall C Pooler
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Karen Park
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Lucy Xia
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Jonathan Tyrer
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Laurence N Kolonel
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA
| | - Loic Le Marchand
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA
| | - Robert N Hoover
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Mitchell J Machiela
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Merideth Yeager
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Laurie Burdette
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Charles C Chung
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Amy Hutchinson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Kai Yu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Chee Goh
- Institute of Cancer Research, London, UK
| | | | | | | | - Teuvo L J Tammela
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Anssi Auvinen
- Department of Epidemiology, School of Health Sciences, University of Tampere, Tampere, Finland
| | - Tiina Wahlfors
- BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland
| | - Johanna Schleutker
- 1] BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland. [2] Department of Medical Biochemistry, Institute of Biomedicine, University of Turku, Turku, Finland
| | - Tapio Visakorpi
- Institute of Biomedical Technology/BioMediTech, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Katri A Leinonen
- Institute of Biomedical Technology/BioMediTech, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Jianfeng Xu
- Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Markus Aly
- 1] Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. [2] Department of Clinical Sciences at Danderyds Hospital, Stockholm, Sweden
| | - Jenny Donovan
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Tim J Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Afshan Siddiq
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK
| | - Federico Canzian
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Kay-Tee Khaw
- Clinical Gerontology Unit, University of Cambridge, Cambridge, UK
| | - Atsushi Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Michiaki Kubo
- Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Paul Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Nora Pashayan
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Maren Weischer
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Borge G Nordestgaard
- 1] Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. [2] Faculty of Healthy and Medical Sciences, University of Copenhagen, Herlev, Denmark
| | - Sune F Nielsen
- 1] Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. [2] Faculty of Healthy and Medical Sciences, University of Copenhagen, Herlev, Denmark
| | - Peter Klarskov
- Department of Urology, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Martin Andreas Røder
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Peter Iversen
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | | | | | | | - Janet L Stanford
- 1] Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. [2] Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA
| | - Suzanne Kolb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Sarah Holt
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Beatrice Knudsen
- Translational Pathology, Cedars-Sinai, Los Angeles, California, USA
| | | | - Susan M Gapstur
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA
| | - W Ryan Diver
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA
| | - Victoria L Stevens
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA
| | | | - Manuel Luedeke
- Department of Urology, University Hospital Ulm, Ulm, Germany
| | - Kathleen Herkommer
- Department of Urology, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany
| | | | - Sara S Strom
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Curtis Pettaway
- Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Edward D Yeboah
- 1] University of Ghana Medical School, Accra, Ghana. [2] Korle Bu Teaching Hospital, Accra, Ghana
| | - Yao Tettey
- 1] University of Ghana Medical School, Accra, Ghana. [2] Korle Bu Teaching Hospital, Accra, Ghana
| | - Richard B Biritwum
- 1] University of Ghana Medical School, Accra, Ghana. [2] Korle Bu Teaching Hospital, Accra, Ghana
| | - Andrew A Adjei
- 1] University of Ghana Medical School, Accra, Ghana. [2] Korle Bu Teaching Hospital, Accra, Ghana
| | - Evelyn Tay
- 1] University of Ghana Medical School, Accra, Ghana. [2] Korle Bu Teaching Hospital, Accra, Ghana
| | | | | | - Anand P Chokkalingam
- School of Public Health, University of California, Berkeley, Berkeley, California, USA
| | - Lisa Cannon-Albright
- 1] Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. [2] George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Dominika Wokołorczyk
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Wojciech Kluźniak
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Jong Park
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Thomas Sellers
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Hui-Yi Lin
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA
| | - William B Isaacs
- James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, Maryland, USA
| | - Alan W Partin
- James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, Maryland, USA
| | - Hermann Brenner
- 1] Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. [2] German Cancer Consortium, Heidelberg, Germany
| | - Aida Karina Dieffenbach
- 1] Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. [2] German Cancer Consortium, Heidelberg, Germany
| | | | - Constance Chen
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Edward L Giovannucci
- 1] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Jing Ma
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Meir Stampfer
- 1] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. [3] Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Kathryn L Penney
- 1] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Lorelei Mucci
- 1] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Esther M John
- 1] Cancer Prevention Institute of California, Fremont, California, USA. [2] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA
| | - Sue A Ingles
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Rick A Kittles
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Adam B Murphy
- Department of Urology, Northwestern University, Chicago, Illinois, USA
| | - Hardev Pandha
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - Agnieszka Michael
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - Andrzej M Kierzek
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - William Blot
- 1] International Epidemiology Institute, Rockville, Maryland, USA. [2] Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Lisa B Signorello
- 1] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Demetrius Albanes
- Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Jarmo Virtamo
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| | - Stephanie Weinstein
- Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA
| | - Barbara Nemesure
- Department of Preventive Medicine, Stony Brook University, Stony Brook, New York, USA
| | - John Carpten
- Translational Genomics Research Institute, Phoenix, Arizona, USA
| | - Cristina Leske
- Department of Preventive Medicine, Stony Brook University, Stony Brook, New York, USA
| | - Suh-Yuh Wu
- Department of Preventive Medicine, Stony Brook University, Stony Brook, New York, USA
| | - Anselm Hennis
- 1] Department of Preventive Medicine, Stony Brook University, Stony Brook, New York, USA. [2] Chronic Disease Research Centre, University of the West Indies, Bridgetown, Barbados
| | - Adam S Kibel
- Division of Urologic Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Benjamin A Rybicki
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA
| | | | - Ann W Hsing
- 1] Cancer Prevention Institute of California, Fremont, California, USA. [2] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA
| | - Lisa Chu
- 1] Cancer Prevention Institute of California, Fremont, California, USA. [2] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA
| | - Phyllis J Goodman
- Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Eric A Klein
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - S Lilly Zheng
- Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Judith Clements
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Amanda Spurdle
- Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Manuel R Teixeira
- 1] Department of Genetics, Portuguese Oncology Institute, Porto, Portugal. [2] Biomedical Sciences Institute, University of Porto, Porto, Portugal
| | - Paula Paulo
- Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
| | - Sofia Maia
- Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
| | - Chavdar Slavov
- Department of Urology, Medical University-Sofia, Sofia, Bulgaria
| | - Radka Kaneva
- Department of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University-Sofia, Sofia, Bulgaria
| | - Vanio Mitev
- Department of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University-Sofia, Sofia, Bulgaria
| | - John S Witte
- 1] Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA. [2] Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
| | - Graham Casey
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Elizabeth M Gillanders
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
| | - Daniella Seminara
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Freddie C Hamdy
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - Gerhard A Coetzee
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
| | - Qiyuan Li
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Matthew L Freedman
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - David J Hunter
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Kenneth Muir
- 1] Institute of Population Health, University of Manchester, Manchester, UK. [2] Warwick Medical School, University of Warwick, Coventry, UK
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - David E Neal
- 1] Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK. [2] Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| | - Melissa Southey
- Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia
| | - Graham G Giles
- 1] Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia. [2] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
| | - Gianluca Severi
- 1] Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia. [2] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. [3] Human Genetics Foundation, Torino, Italy
| | - Michael B Cook
- 1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA. [2]
| | - Hidewaki Nakagawa
- 1] Laboratory for Genome Sequencing Analysis, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan. [2]
| | - Fredrik Wiklund
- 1] Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. [2]
| | - Peter Kraft
- 1] Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA. [3]
| | - Stephen J Chanock
- 1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA. [2]
| | - Brian E Henderson
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. [3]
| | - Douglas F Easton
- 1] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [2]
| | - Rosalind A Eeles
- 1] Institute of Cancer Research, London, UK. [2] Royal Marsden National Health Service (NHS) Foundation Trust, London and Sutton, UK. [3]
| | - Christopher A Haiman
- 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. [3]
| |
Collapse
|
109
|
Jordanov S, Pierini S, Chalakov I, Mitev V, Melnicharov M, Kaneva R, Goranova T. Mgmt Promoter Hypermethylation As a Prognostic Factor in Patients with Laryngeal Squamous Cell Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu325.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
110
|
Kamenarska Z, Dzhebir G, Hristova M, Savov A, Vinkov A, Kaneva R, Mitev V, Dourmishev L. IL-1RN VNTR Polymorphism in Adult Dermatomyositis and Systemic Lupus Erythematosus. Dermatol Res Pract 2014; 2014:953597. [PMID: 25328514 PMCID: PMC4156996 DOI: 10.1155/2014/953597] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2014] [Accepted: 08/07/2014] [Indexed: 02/05/2023] Open
Abstract
Polymorphisms in the cytokine genes and their natural antagonists are thought to influence the predisposition to dermatomyositis (DM) and systemic lupus erythematosus (SLE). A variable number tandem repeat (VNTR) polymorphism of 86 bp in intron 2 of the interleukin-1 receptor antagonist (IL-1RN) gene leads to the existence of five different alleles which cause differences in the production of both IL-1RA (interleukin-1 receptor antagonist) and IL-1β. The aim of this case-control study was to investigate the association between the IL-1RN VNTR polymorphism and the susceptibility to DM and SLE in Bulgarian patients. Altogether 91 patients, 55 with SLE and 36 with DM, as well as 112 unrelated healthy controls, were included in this study. Only three alleles were identified in both patients and controls ((1) four repeats, (2) two repeats, and (3) five repeats). The IL-1RN*2 allele (P = 0.02, OR 2.5, and 95% CI 1.2-5.4) and the 1/2+2/2 genotypes were found prevalent among the SLE patients (P = 0.05, OR 2.6, and 95% CI 1-6.3). No association was found between this polymorphism and the ACR criteria for SLE as well as with the susceptibility to DM. Our results indicate that the IL-1RN VNTR polymorphism might play a role in the susceptibility of SLE but not DM.
Collapse
Affiliation(s)
- Zornitsa Kamenarska
- Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Gyulnas Dzhebir
- Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Maria Hristova
- Department of Clinical Laboratory and Clinical Immunology and Department of Nephrology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria
| | - Alexey Savov
- National Genetic Laboratory, Maichin Dom Hospital, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Anton Vinkov
- 28 Diagnostic and Consultative Center-Sofia, 1 Iliya Beshkov Street, 1592 Sofia, Bulgaria
| | - Radka Kaneva
- Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Lyubomir Dourmishev
- Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria
| |
Collapse
|
111
|
Pendicheva D, Tzveova R, Dimitrova-Karamfilova A, Naydenova G, Atanasov P, Mitkova A, Nachev G, Mitev V, Kaneva R. Genetic Polymorphisms In Clopidogrel And Acenocoumarol-Related Genes And Their Frequencies In South-Eastern European Population. Clin Ther 2014. [DOI: 10.1016/j.clinthera.2014.05.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
112
|
Setchanova LP, Alexandrova A, Dacheva D, Mitov I, Kaneva R, Mitev V. Dominance of multidrug-resistant Denmark(14)-32 (ST230) clone among Streptococcus pneumoniae serotype 19A isolates causing pneumococcal disease in Bulgaria from 1992 to 2013. Microb Drug Resist 2014; 21:35-42. [PMID: 25080213 DOI: 10.1089/mdr.2014.0076] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
A pneumococcal conjugate vaccine (PCV10) was introduced in Bulgarian national immunization program since April 2010. Clonal composition based on pulsed-field gel electrophoresis and multilocus sequence typing genotyping of 52 serotype 19A Streptococcus pneumoniae isolates was analyzed. These were invasive and respiratory isolates collected between 1992 and 2013 from both children (78.8% <5 years) and adults with pneumococcal infections. Multidrug resistance was found in 82.7% of all 19A isolates. The most prevalent genotype (63.5%) among serotype 19A pneumococcal strains was the multidrug-resistant clonal complex CC230, which is a capsular switched variant of the Denmark(14)-32 (ST230) global clone. The most frequent sequence type (ST) was ST230 (48.1%) and together with four other closely related STs (15.4%), belonging to ST1611, ST276, ST7466, and ST2013, which were single- and double-locus variants; they were included in the main CC230. The disappearance of highly drug-resistant ST663 clone and emergence of new clones as CC320 and CC199 was also observed among the rest 19A isolates. A comparison of clonal composition between invasive and noninvasive isolates did not show a great genetic diversity among both kinds of isolates. Continuous surveillance of serotype 19A population following the introduction of PCV10 is essential to evaluate the impact of the vaccine on the epidemiology of this serotype.
Collapse
Affiliation(s)
- Lena Petrova Setchanova
- 1 Department of Medical Microbiology, Faculty of Medicine, Medical University of Sofia , Sofia, Bulgaria
| | | | | | | | | | | |
Collapse
|
113
|
Kachakova D, Popov E, Mitkova A, Popov I, Vlahova A, Dikov T, Christova S, Slavov C, Mitev V, Kaneva R. 397: miR-141 and miR-375 expression in plasma samples from Bulgarian prostate cancer patients and controls. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50354-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
114
|
Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Poptodorov G, Kaneva R, Mitev V, Gabrovsky N. 698: Gene expression of SOX2, SOX6, SOX8 and SOX9 and their prognostic role in patients with gliomas. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50616-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
115
|
Dacheva D, Popov I, Dodova R, Goranova T, Mitkova A, Kaneva R, Mitev V. 432: Comparison of two library construction strategies for targeted resequencing of BRCA1/2 genes in Bulgarian breast cancer patients on NGS platform. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50386-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
116
|
Dodova R, Mitkova A, Dacheva D, Taushanova M, Valev S, Vlahova A, Dikov T, Timcheva C, Christova S, Kaneva R. 583: Recurrent BRCA1/2 mutations in Bulgarian patients with hereditary breast and ovarian cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50518-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
117
|
Shumnalieva R, Kachakova D, Monov S, Kaneva R, Kolarov Z, Rashkov R. AB0142 Mir-223 Expression Profile as A Biomarker in Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
118
|
Dourmishev L, Kamenarska Z, Kaneva R, Mitev V, Hristova M, Andonova S, Savov A. Association between estrogen receptor-α gene polymorphisms and dermatomyositis in Bulgarian patients. Int J Dermatol 2014; 53:e363-4. [DOI: 10.1111/ijd.12322] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Lyubomir Dourmishev
- Department of Dermatology and Venereology; Medical University-Sofia; Sofia Bulgaria
| | - Zornitsa Kamenarska
- Department of Molecular Medicine Center; Medical University-Sofia; Sofia Bulgaria
| | - Radka Kaneva
- Department of Molecular Medicine Center; Medical University-Sofia; Sofia Bulgaria
| | - Vanio Mitev
- Department of Molecular Medicine Center; Medical University-Sofia; Sofia Bulgaria
| | - Maria Hristova
- Departmant of Clinical and Laboratory Immunology; Medical University-Sofia; Sofia Bulgaria
| | - Silvia Andonova
- National Genetics Laboratory; Majchin Dom Hospital; Sofia Bulgaria
| | - Alexey Savov
- National Genetics Laboratory; Majchin Dom Hospital; Sofia Bulgaria
| |
Collapse
|
119
|
Shumnalieva R, Kachakova D, Monov S, Kaneva R, Kolarov Z, Rashkov R. A5.16 miRNA expression profile in Bulgarian patients with rheumatoid arthritis compared to patients with osteoarthritis and healthy controls in regard to their use as biomarkers in the clinical practice. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-205124.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
120
|
Saunders EJ, Dadaev T, Leongamornlert DA, Jugurnauth-Little S, Tymrakiewicz M, Wiklund F, Al Olama AA, Benlloch S, Neal DE, Hamdy FC, Donovan JL, Giles GG, Severi G, Gronberg H, Aly M, Haiman CA, Schumacher F, Henderson BE, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Nordestgaard BG, Canzian F, Campa D, Riboli E, Key TJ, Travis RC, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Clements JA, Teixeira MR, Xu J, Mikropoulos C, Goh C, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Easton DF, Muir K, Eeles RA, Kote-Jarai Z. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet 2014; 10:e1004129. [PMID: 24550738 PMCID: PMC3923678 DOI: 10.1371/journal.pgen.1004129] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 12/06/2013] [Indexed: 02/02/2023] Open
Abstract
The HOXB13 gene has been implicated in prostate cancer (PrCa) susceptibility. We performed a high resolution fine-mapping analysis to comprehensively evaluate the association between common genetic variation across the HOXB genetic locus at 17q21 and PrCa risk. This involved genotyping 700 SNPs using a custom Illumina iSelect array (iCOGS) followed by imputation of 3195 SNPs in 20,440 PrCa cases and 21,469 controls in The PRACTICAL consortium. We identified a cluster of highly correlated common variants situated within or closely upstream of HOXB13 that were significantly associated with PrCa risk, described by rs117576373 (OR 1.30, P = 2.62×10(-14)). Additional genotyping, conditional regression and haplotype analyses indicated that the newly identified common variants tag a rare, partially correlated coding variant in the HOXB13 gene (G84E, rs138213197), which has been identified recently as a moderate penetrance PrCa susceptibility allele. The potential for GWAS associations detected through common SNPs to be driven by rare causal variants with higher relative risks has long been proposed; however, to our knowledge this is the first experimental evidence for this phenomenon of synthetic association contributing to cancer susceptibility.
Collapse
Affiliation(s)
| | - Tokhir Dadaev
- The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | | | | | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Ali Amin Al Olama
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | - Sara Benlloch
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | - David E. Neal
- Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Addenbrooke's Hospital, Cambridge and Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom
| | - Freddie C. Hamdy
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, and Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
| | - Jenny L. Donovan
- School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Graham G. Giles
- Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria, Australia and Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria, Australia
| | - Gianluca Severi
- Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria, Australia and Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria, Australia
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Markus Aly
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Christopher A. Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States of America
| | - Fredrick Schumacher
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States of America
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States of America
| | - Sara Lindstrom
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
| | - Peter Kraft
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
| | - David J. Hunter
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
| | - Susan Gapstur
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America
| | - Stephen Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, United States of America
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, United States of America
| | - Demetrius Albanes
- Nutritional Epidemiology Branch, National Cancer Institute, NIH, EPS-3044, Bethesda, Maryland, United States of America
| | - Gerald Andriole
- Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Johanna Schleutker
- Department of Medic Biochemistry and Genetics, University of Turku, Turku and Institute of Biomedical Technology and BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland
| | - Maren Weischer
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Børge G. Nordestgaard
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Federico Canzian
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Daniele Campa
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Elio Riboli
- Department of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Tim J. Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Sue A. Ingles
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States of America
| | - Esther M. John
- Cancer Prevention Institute of California, Fremont, California, United States of America, and Stanford University School of Medicine, Stanford, California, United States of America
| | - Richard B. Hayes
- Division of Epidemiology, Department of Population Health, NYU Langone Medical Center, NYU Cancer Institute, New York, New York, United States of America
| | - Paul Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | - Kay-Tee Khaw
- Clinical Gerontology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Janet L. Stanford
- Department of Epidemiology, School of Public Health, University of Washington and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
| | - Elaine A. Ostrander
- National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Lisa B. Signorello
- International Epidemiology Institute, Rockville, Maryland, and Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | | | - Daniel Schaid
- Mayo Clinic, Rochester, Minnesota, United States of America
| | - Christiane Maier
- Department of Urology, University Hospital Ulm and Institute of Human Genetics University Hospital Ulm, Ulm, Germany
| | - Adam S. Kibel
- Division of Urologic Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Lisa Cannon-Albright
- Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine and George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States of America
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jong Y. Park
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America
| | - Radka Kaneva
- Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University - Sofia, Sofia, Bulgaria
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Judith A. Clements
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Manuel R. Teixeira
- Biomedical Sciences Institute (ICBAS), Porto University, Porto, and Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
| | - Jianfeng Xu
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
| | | | - Chee Goh
- The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | - Michelle Guy
- The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | - Emma J. Sawyer
- The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | - Angela Morgan
- The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | | | | | | | - Douglas F. Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom
| | - Ken Muir
- Warwick Medical School, University of Warwick, Coventry, United Kingdom
| | | | | |
Collapse
|
121
|
Djarova T, Bardarev D, Boyanov D, Kaneva R, Atanasov P. Performance enhancing genetic variants, oxygen uptake, heart rate, blood pressure and body mass index of elite high altitude mountaineers. ACTA ACUST UNITED AC 2013; 100:289-301. [PMID: 24058088 DOI: 10.1556/aphysiol.100.2013.3.5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
AIM To analyse and compare the ACE (angiotensin-converting enzyme), ACTN3 (actinin-3) and AMPD1 (adenosine monophosphate deaminase 1) genetic variants, oxygen uptake (VO2max), heart rate (HR), blood pressure (BP) and body mass index (BMI) of elite high altitude mountaineers and average athletes. METHODS Elite Bulgarian alpinists (n = 5) and control group of athletes (n = 72) were recruited. VO2max was measured using a treadmill graded protocol. HR, BP and BMI were recorded. Genotyping was done by polymerase chain reaction (PCR) amplification followed by agarose gel electrophoresis. Chi2-test and Fisher's exact test were used for statistical analysis. RESULTS Alpinists showed significantly higher frequencies of 60% ACE I allele (p = 0.002), 50% ACTN3 X allele (p = 0.032) and 30% AMPD1 T allele (p = 0.003) compared to controls - 39%, 36%, 13%, respectively. ACE ID genotype prevalence and null DD genotype were observed in mountaineers. Higher absolute VO2max, but no differences in VO2max ml kg-1 min-1, HR, oxygen pulse, blood pressure and BMI were found. CONCLUSIONS The ID genotype and higher frequencies of ACE I allele could contribute to successful high altitude ascents in mountaineers. The genetic make-up of the two mountaineers who made the summit of Mt Everest was distinctive, revealing ACE ID genotype, mutant ACTN3 XX and AMPD1 TT genotypes.
Collapse
Affiliation(s)
- T Djarova
- University of Zululand, South Africa Department of Biochemistry and Microbiology Private Bag X1001 KwaDlangezwa 3886 South Africa
| | | | | | | | | |
Collapse
|
122
|
Hristova M, Dourmishev L, Kamenarska Z, Miteva L, Vinkov A, Kaneva R, Mitev V, Savov A. MBL2polymorphisms - manifestations in Bulgarian patients with adult dermatomyositis and systemic lupus erythematosus. Int J Immunogenet 2013; 41:119-25. [DOI: 10.1111/iji.12093] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Revised: 08/12/2013] [Accepted: 08/25/2013] [Indexed: 11/30/2022]
Affiliation(s)
- M. Hristova
- Department of Clinical Laboratory and Clinical Immunology; Medical University-Sofia; Sofia Bulgaria
| | - L. Dourmishev
- Department of Dermatology and Venereology; Medical University-Sofia; Sofia Bulgaria
| | - Z. Kamenarska
- Molecular Medicine Center; Medical University-Sofia and Department of Medical Chemistry and Biochemistry; Medical University-Sofia; Sofia Bulgaria
| | - L. Miteva
- Department of Dermatology and Venereology; Medical University-Sofia; Sofia Bulgaria
| | - A. Vinkov
- XXVIII Diagnostic and Consultative Centre; Sofia Bulgaria
| | - R. Kaneva
- Molecular Medicine Center; Medical University-Sofia and Department of Medical Chemistry and Biochemistry; Medical University-Sofia; Sofia Bulgaria
| | - V. Mitev
- Molecular Medicine Center; Medical University-Sofia and Department of Medical Chemistry and Biochemistry; Medical University-Sofia; Sofia Bulgaria
| | - A. Savov
- National Genetic Laboratory; Majchin Dom Hospital; Sofia Bulgaria
| |
Collapse
|
123
|
Hristova M, Dourmishev L, Kamenarska Z, Nikolova S, Kaneva R, Vinkov A, Baleva M, Monova D, Mitev V. Role of the promoter polymorphism IL-6 -174G/C in dermatomyositis and systemic lupus erythematosus. Biomed Res Int 2013; 2013:315365. [PMID: 24106699 PMCID: PMC3784074 DOI: 10.1155/2013/315365] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Revised: 07/29/2013] [Accepted: 08/12/2013] [Indexed: 02/02/2023]
Abstract
The promoter polymorphism -174G/C within the interleukin-6 gene (IL-6) has been reported to have a functional importance through the modulation of IL-6 gene expression in vitro and in vivo. IL-6 is thought to play an important role in autoimmune diseases and the effect of its receptor inhibitor-tocilizumab-has been recently studied. The aim of this case-control study was to investigate the association between the interleukin-6 -174G/C single nucleotide polymorphism and the susceptibility to dermatomyositis (DM) and systemic lupus erythematosus (SLE) in Bulgarian patients. Altogether, 87 patients-52 with SLE and 35 with DM-as well as 80 unrelated healthy controls were included in this study. All of them were analyzed by restriction fragment length polymorphism analysis (RFLP). The GG genotype and the G allele appeared to be associated with SLE, especially in women. None of the genotypes showed an association with DM. However, the G allele appeared to be associated with muscle weakness and it is a risk factor for elevated muscle enzymes. Our results indicate that IL-6 -174G/C polymorphism might be associated with the susceptibility to SLE especially in women. Although it is not associated with DM, it seems that IL-6 -174G/C polymorphism could modulate some clinical features in the autoimmune myopathies.
Collapse
Affiliation(s)
- Maria Hristova
- Department of Clinical Laboratory and Clinical Immunology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria
| | - Lyubomir Dourmishev
- Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria
| | - Zornitsa Kamenarska
- Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
- Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Svetla Nikolova
- Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
- Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Radka Kaneva
- Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
- Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| | - Anton Vinkov
- 28 Diagnostic and Consultative Center-Sofia, 1 Iliya Beshkov Street, 1592 Sofia, Bulgaria
| | - Marta Baleva
- Department of Clinical Laboratory and Clinical Immunology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria
| | - Daniela Monova
- Department of Nephrology, Ministry of Interior Hospital, 79 Skobelev Boulevard, 1606 Sofia, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
- Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
| |
Collapse
|
124
|
Yaneva‐Sirakova T, Tarnovska‐Kadreva R, Traykov L, Naydenov K, Zveova R, Kaneva R, Mitev V, Kremenski I. P4–176: Genetic screening for mild cognitive impairment in people with cardiovascular risk factors. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.1567] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Teodora Yaneva‐Sirakova
- Medical University Sofia, University Hospital “Alexandrovska”, Cardiology Clinic Sofia Bulgaria
| | | | - Latchezar Traykov
- Medical University Sofia, University Hospital “Alexandrovska”, Neurology Clinic Sofia Bulgaria
| | - Kiril Naydenov
- Medical University Sofia Department Medical Chemistry and Biochemistry Sofia Bulgaria
| | - Reni Zveova
- Medical University Sofia, Molecular Medicine Center Sofia Bulgaria
| | - Radka Kaneva
- Medical University Sofia, Molecular Medicine Center Sofia Bulgaria
| | - Vanio Mitev
- Medical University Sofia, Molecular Medicine Center Sofia Bulgaria
| | - Ivo Kremenski
- Medical University Sofia National Genetic Laboratory Sofia Bulgaria
| |
Collapse
|
125
|
Kachakova D, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, Hristova S, Mitev V, Slavov C, Kaneva R. Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients. J BUON 2013; 18:660-668. [PMID: 24065480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
PURPOSE Searching for diagnostic and prognostic biomarkers for prostate cancer (PC) is main public health priority. DNA methylation in body fluids is a stable, easily detectable and promising PC biomarker. The major advantages of urine-based assays are their noninvasive nature and the ability to monitor PC with heterogeneous foci. The aim of this study was to determine the diagnostic value of the recently identified candidate PC biomarker HIST1H4K. METHODS We investigated DNA methylation of HIST1H4K in urine samples from 57 PC patients, 29 controls with benign prostatic hyperplasia (BPH) and 50 young asymptomatic men (YAM) by MethyLight real-time PCR. RESULTS The frequency of HIST1H4K promoter hypermethylation significantly discriminated PC patients from YAM (AUC =0.763; 95% CI 0.672-0.839; p<0.0001), but did not show any statistical difference between PC patients and BPH controls (AUC=0.513, 95% CI 0.402-0.622; p=0.8255). HIST1H4K could not outperform the prostatic specific antigen (PSA) in our sample (AUC=0.785; 95% CI 0.679-0.870; p<0.0001). Methylation of HIST1H4K showed significant correlation with aging (r=0.5418; p<0.0001), but with no other clinicopathological characteristics. CONCLUSION The results suggest that the promoter hypermethylation of HIST1H4K is rather due to aging than related to prostate carcinogenesis. To elucidate this observation analysis of larger samples is needed.
Collapse
Affiliation(s)
- D Kachakova
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University-Sofia, Sofia, Bulgaria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
126
|
Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russell R, Russel R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC, Easton DF, Eeles RA. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013; 22:2520-8. [PMID: 23535824 PMCID: PMC3658165 DOI: 10.1093/hmg/ddt086] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 02/18/2013] [Indexed: 01/18/2023] Open
Abstract
Associations between single nucleotide polymorphisms (SNPs) at 5p15 and multiple cancer types have been reported. We have previously shown evidence for a strong association between prostate cancer (PrCa) risk and rs2242652 at 5p15, intronic in the telomerase reverse transcriptase (TERT) gene that encodes TERT. To comprehensively evaluate the association between genetic variation across this region and PrCa, we performed a fine-mapping analysis by genotyping 134 SNPs using a custom Illumina iSelect array or Sequenom MassArray iPlex, followed by imputation of 1094 SNPs in 22 301 PrCa cases and 22 320 controls in The PRACTICAL consortium. Multiple stepwise logistic regression analysis identified four signals in the promoter or intronic regions of TERT that independently associated with PrCa risk. Gene expression analysis of normal prostate tissue showed evidence that SNPs within one of these regions also associated with TERT expression, providing a potential mechanism for predisposition to disease.
Collapse
Affiliation(s)
- Zsofia Kote-Jarai
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
127
|
Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PDP, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TLJ, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Kote-Jarai Z, Easton DF. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45:385-91, 391e1-2. [PMID: 23535732 PMCID: PMC3832790 DOI: 10.1038/ng.2560] [Citation(s) in RCA: 431] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Accepted: 01/28/2013] [Indexed: 12/13/2022]
Abstract
Prostate cancer is the most frequently diagnosed cancer in males in developed countries. To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a custom Illumina array (iCOGS) in blood DNA from 25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL Consortium. Twenty-three new prostate cancer susceptibility loci were identified at genome-wide significance (P < 5 × 10(-8)). More than 70 prostate cancer susceptibility loci, explaining ∼30% of the familial risk for this disease, have now been identified. On the basis of combined risks conferred by the new and previously known risk loci, the top 1% of the risk distribution has a 4.7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies.
Collapse
|
128
|
Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013; 22:408-15. [PMID: 23065704 PMCID: PMC3526158 DOI: 10.1093/hmg/dds425] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Accepted: 10/04/2012] [Indexed: 01/14/2023] Open
Abstract
Genome-wide association studies (GWAS) have identified multiple common genetic variants associated with an increased risk of prostate cancer (PrCa), but these explain less than one-third of the heritability. To identify further susceptibility alleles, we conducted a meta-analysis of four GWAS including 5953 cases of aggressive PrCa and 11 463 controls (men without PrCa). We computed association tests for approximately 2.6 million SNPs and followed up the most significant SNPs by genotyping 49 121 samples in 29 studies through the international PRACTICAL and BPC3 consortia. We not only confirmed the association of a PrCa susceptibility locus, rs11672691 on chromosome 19, but also showed an association with aggressive PrCa [odds ratio = 1.12 (95% confidence interval 1.03-1.21), P = 1.4 × 10(-8)]. This report describes a genetic variant which is associated with aggressive PrCa, which is a type of PrCa associated with a poorer prognosis.
Collapse
Affiliation(s)
- Ali Amin Al Olama
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - Zsofia Kote-Jarai
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Fredrick R. Schumacher
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm SE-171 77, Sweden
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
- Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, Gaithersburg, MD, USA
| | - Sara Benlloch
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - Graham G. Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, 723 Swanston Street, Carlton, VIC 3053, Australia
| | - Gianluca Severi
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, 723 Swanston Street, Carlton, VIC 3053, Australia
| | - David E. Neal
- Surgical Oncology (Uro-Oncology: S4), Addenbrooke's Hospital, University of Cambridge, Box 279, Hills Road, Cambridge, UK
- Li Ka Shing Centre, Cancer Research UK Cambridge Research Institute, Cambridge CB2 2QQ, UK
| | - Freddie C. Hamdy
- Nuffield Department of Surgery and
- Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
| | - Jenny L. Donovan
- School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
| | - David J. Hunter
- Program in Molecular and Genetic Epidemiology, Department of Epidemiology and
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Michael J. Thun
- Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
| | - Michael Gaziano
- Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research, Education, and Clinical Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, MA 02114, USA
- Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA
| | | | - Afshan Siddiq
- Department of Genomics of Common Disease, School of Public Health, Imperial College, London SW7 2AZ, UK
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - David G. Cox
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK
- Lyon Cancer Research Center, INSERM U1052, Lyon, France
| | | | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK
| | - Timothy J. Key
- Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Gerald Andriole
- Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
| | - Richard B. Hayes
- Division of Epidemiology, Department of Environmental Medicine, NYU Langone Medical Centre, NYU Cancer Institute, New York, NY 10016, USA
| | - Johanna Schleutker
- Institute of Biomedical Technology/BioMediTech, University of Tampere and
- Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland
| | - Anssi Auvinen
- Department of Epidemiology, School of Health Sciences and
| | - Teuvo L.J. Tammela
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | | | - Janet L. Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
| | - Elaine A. Ostrander
- National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Room 5351, Bethesda, MD, USA
| | - Cezary Cybulski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | | | | | | | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
| | - Judith A. Clements
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
| | - Suzanne Chambers
- Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia
- Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, QLD, Australia
- Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia
| | - Joanne Aitken
- Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, QLD, Australia
| | - Robert A. Gardiner
- Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia
| | - Christiane Maier
- Department of Urology and
- Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Walther Vogel
- Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Thilo Dörk
- Hannover Medical School, Hannover, Germany
| | | | - Tomonori Habuchi
- Department of Urology,Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Sue Ingles
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Esther M. John
- Cancer Prevention Institute of California, Fremont, CA, USA
- Division of Epidemiology, Department of Health Research and Policy and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Joanne L. Dickinson
- Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia
| | - Lisa Cannon-Albright
- Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Centre, Salt Lake City, UT, USA
| | - Manuel R. Teixeira
- Department of Genetics, Portuguese Oncology Institute and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Radka Kaneva
- Molecular Medicine Centre, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 2 Zdrave St, Sofia 1431, Bulgaria
| | - Hong-Wei Zhang
- Department of Epidemiology, Second Military Medical University, Shanghai, China
| | - Yong-Jie Lu
- Centre for Molecular Oncology and Imaging, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK
| | - Jong Y. Park
- Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Centre, 12902 Magnolia Drive, Tampa, FL, USA
| | - Kathleen A. Cooney
- Department of Internal Medicine and
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA
| | | | | | - Edward Saunders
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | | | - Nadiya Mahmud
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Michelle Guy
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Koveela Govindasami
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Lynne T. O'Brien
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | | | - Amanda L. Hall
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Emma J. Sawyer
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Tokhir Dadaev
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Jonathan Morrison
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - David P. Dearnaley
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Alan Horwich
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Robert A. Huddart
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Vincent S. Khoo
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Christopher C. Parker
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Nicholas Van As
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | | | - Alan Thompson
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Tim Dudderidge
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Chris Ogden
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Colin S. Cooper
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | | | - Melissa C. Southey
- Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Grattan street, Parkville, VIC, Australia
| | - John L. Hopper
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC, Australia
| | - Dallas English
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, 723 Swanston Street, Carlton, VIC, Australia
| | - Jarmo Virtamo
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| | - Loic Le Marchand
- Epidemiology Program, University of Hawaii Cancer Centre, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
| | - Daniele Campa
- Lyon Cancer Research Center, INSERM U1052, Lyon, France
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Sara Lindstrom
- Program in Molecular and Genetic Epidemiology, Department of Epidemiology and
| | - W. Ryan Diver
- Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
| | - Susan Gapstur
- Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
| | - Meredith Yeager
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
- Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, Gaithersburg, MD, USA
| | - Angela Cox
- Department of Oncology, University of Sheffield, Sheffield, UK
| | - Mariana C. Stern
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Roman Corral
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Markus Aly
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm SE-171 77, Sweden
- Division of Urology, Department of Clinical Sciences, Danderyd Hospital and
| | - William Isaacs
- School of Medicine, Johns Hopkins University, 115 Marburg Building, 600 North Wolfe Street, Baltimore, MD 21205, USA
| | - Jan Adolfsson
- Oncological Centre, CLINTEC, Karolinska Institute, Stockholm, Sweden
| | - Jianfeng Xu
- Center for Cancer Genomics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
| | - S. Lilly Zheng
- Center for Cancer Genomics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
| | - Tiina Wahlfors
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Kimmo Taari
- Department of Urology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
| | - Paula Kujala
- Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland
| | - Peter Klarskov
- Department of Urology, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark
| | | | | | - Ruth Frikke-Schmidt
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen DK-2100, Denmark
| | | | - Liesel M. FitzGerald
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
| | - Suzanne Kolb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
| | - Erika M. Kwon
- National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Room 5351, Bethesda, MD, USA
| | - Danielle M. Karyadi
- National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Room 5351, Bethesda, MD, USA
| | | | - Michael Borre
- Department of Urology, Aarhus University Hospital, Skejby, Denmark
| | | | - Manuel Luedeke
- Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Kathleen Herkommer
- Department of Urology, Rechts der Isar Medical Centre, Technical University of Munich, Munich, Germany
| | | | | | - James R. Marthick
- Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia
| | - Briony Patterson
- Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia
| | - Dominika Wokolorczyk
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | | | - Felicity Lose
- Molecular Cancer Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, QLD, Australia
| | | | - Amit D. Joshi
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Ahva Shahabi
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Pedro Pinto
- Department of Genetics, Portuguese Oncology Institute and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Joana Santos
- Department of Genetics, Portuguese Oncology Institute and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Ana Ray
- Department of Internal Medicine and
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Thomas A. Sellers
- Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Centre, 12902 Magnolia Drive, Tampa, FL, USA
| | - Hui-Yi Lin
- Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Centre, 12902 Magnolia Drive, Tampa, FL, USA
| | | | - Craig Teerlink
- Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Heiko Muller
- Division of Clinical Epidemiology and Aging Research and
| | | | - Norihiko Tsuchiya
- Department of Urology,Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Shintaro Narita
- Department of Urology,Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Guang-Wen Cao
- Department of Epidemiology, Second Military Medical University, Shanghai, China
| | - Chavdar Slavov
- Department of Urology and Alexandrovska University Hospital,Medical University of Sofia, Sofia, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Centre, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 2 Zdrave St, Sofia 1431, Bulgaria
| | | | | | | | | | - Stephen Chanock
- Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, Gaithersburg, MD, USA
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm SE-171 77, Sweden
| | - Christopher A. Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Peter Kraft
- Program in Molecular and Genetic Epidemiology, Department of Epidemiology and
| | - Douglas F. Easton
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - Rosalind A. Eeles
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| |
Collapse
|
129
|
Mendizabal I, Lao O, Marigorta UM, Wollstein A, Gusmão L, Ferak V, Ioana M, Jordanova A, Kaneva R, Kouvatsi A, Kučinskas V, Makukh H, Metspalu A, Netea MG, de Pablo R, Pamjav H, Radojkovic D, Rolleston SJH, Sertic J, Macek M, Comas D, Kayser M. Reconstructing the population history of European Romani from genome-wide data. Curr Biol 2012; 22:2342-9. [PMID: 23219723 DOI: 10.1016/j.cub.2012.10.039] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 08/22/2012] [Accepted: 10/23/2012] [Indexed: 01/21/2023]
Abstract
The Romani, the largest European minority group with approximately 11 million people, constitute a mosaic of languages, religions, and lifestyles while sharing a distinct social heritage. Linguistic and genetic studies have located the Romani origins in the Indian subcontinent. However, a genome-wide perspective on Romani origins and population substructure, as well as a detailed reconstruction of their demographic history, has yet to be provided. Our analyses based on genome-wide data from 13 Romani groups collected across Europe suggest that the Romani diaspora constitutes a single initial founder population that originated in north/northwestern India ~1.5 thousand years ago (kya). Our results further indicate that after a rapid migration with moderate gene flow from the Near or Middle East, the European spread of the Romani people was via the Balkans starting ~0.9 kya. The strong population substructure and high levels of homozygosity we found in the European Romani are in line with genetic isolation as well as differential gene flow in time and space with non-Romani Europeans. Overall, our genome-wide study sheds new light on the origins and demographic history of European Romani.
Collapse
Affiliation(s)
- Isabel Mendizabal
- Departament de Ciències de la Salut i de la Vida, Institut de Biologia Evolutiva (CSIC-UPF), Universitat Pompeu Fabra, 08003 Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
130
|
Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M, Perin A, Verginelli F, Dali R, Hei Man Fung K, Lo R, Longatti P, Guiot M, Del Maestro RF, Rossi S, Di Porzio U, Stechishin O, Weiss S, Stifani S, Sanzey M, Golebiewska A, Stieber D, Nazarov P, Muller A, Vallar L, Niclou SP, Lawler SE, Chiocca E, Williams SP, Wanka C, Steinbach JP, Rieger J, Lavon I, Zrihan D, Refael M, Siegal T, Sminia P, Van Nifterik KA, Van den Berg J, Lafleur VM, Stalpers LJA, Slotman BJ, Di stefano A, Enciso-Mora V, Marie Y, Desestret V, Labussiere M, Idbaih A, Hoang-Xuan K, Delattre J, Houlston R, Sanson M, Woehrer A, Slavc I, Stefanits H, Waldhoer T, Heinzl H, Zielonke N, Czech T, Hainfellner JA, Haberler C, Zouaoui S, Darlix A, Virion J, Rigau V, Mathieu-Daude H, Bauchet F, Figarella-Branger D, Duffau H, Taillandier L, Bauchet L, Naydenov E, Popov R, Tanova R, Minkin K, De Vleeschouwer S, Van Gool S, Cavaletti G, Wilbers J, Hoebers F, Boogerd W, van Werkhoven E, Nowee M, Hart G, van Dijk E, Kappelle A, Dorresteijn L, Furuse M, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Miyatake S, Boele FW, Heimans JJ, Aaronson NK, Peereboom DM, Sloan AE, Supko JG, Ye X, Rich JN, Prados MD, Ahluwalia M, Grossman SA, Spiegl-Kreinecker S, Loetsch D, Taphoorn MJB, Wild M, Ghanim B, Pirker C, Pichler J, Serge W, Lenz S, Wurm G, Berger W, Tamiya T, Miyake K, Postma TJ, Okada M, Kawai N, Grossi I, Rigakos G, Lampropoulos S, Stavridi F, Tsoulos N, Nasioulas G, Papadopoulou E, Razis E, Reijneveld JC, Schroeteler J, Klosterkemper Y, Schwake M, Stummer W, Ewelt C, Field KM, Rosenthal MA, Wheeler H, Cher L, Hovey E, Klein M, Nowak AK, Brown C, Livingstone A, Sawkins K, Simes J, Linsenmann T, Jawork A, Hagemann C, Kessler AF, Berg F, Habets EJJ, Lohr M, Ernestus RI, Vince GH, Rodriguez FJ, Heaphy CM, Nguyen DN, de Wilde RF, Orr B, Raabe E, Eberhart CG, Taphoorn MJB, Meeker AK, Klein SP, Van Calenbergh F, van Loon J, Menten J, Clement P, De Vleeschouwer S, Goffin J, Lonardi F, Gioga G, Nederend S, Bonometti M, Ferigo L, Buonocore F, Campostrini F, Golebiewska A, Bougnaud S, Stieber D, Brons N, Vallar L, Hertel F, Klein M, Bjerkvig R, Niclou S, Strik HM, Carl B, Kallenberg K, Moiyadi AV, Gupta T, Shetty P, Nair V, Jalali R, Delgadillo D, Compter I, de Kunder SL, Houben RMA, Jager JJ, Bosmans G, Anten MHME, Baumert BG, Duerinck J, Du Four S, Van Binst A, Xuan KH, Everaert H, Michotte A, D'haens J, Neyns B, Basmaci M, Hasturk AE, de Kunder SL, Compter I, Schijns OEMG, ter Laak-Poort MP, Bottomley A, Anten MHME, Jansen RLH, Baumert BG, Happold C, Roth P, Wick W, Schmidt N, Florea A, Reifenberger G, Weller M, Van den Bent MJ, Ho C, Leugner D, Easaw J, Lim G, Rosenberg T, Thomassen M, Jensen S, Larsen M, Sorensen K, Hermansen S, Reijneveld JC, Kruse T, Kristensen B, Pichler J, Hollmuller I, Ghanim B, Spiegl-Kreinecker S, Ursu R, Ferrari D, Bailon O, Augier A, Minaya Flores P, Dubessy A, Banissi C, Belin C, Levy C, Carpentier AF, Boudouresque F, Delphino C, Metellus P, Pirisi V, Figarella-Branger D, Chinot O, Ouafik L, Berthois Y, Nakamura H, Makino K, Hide T, Yano S, Kuratsu J, Stevens GHJ, Ahluwalia M, Hashemi N, Berbis J, Peereboom D, Barnett GH, Wibom C, Ghasimi S, Van Loo P, Brannstrom T, Trygg J, Henriksson R, Bergenheim T, Andersson U, Auquier P, Ryden P, Melin B, Ackerl MS, Flechl B, Dieckmann K, Preusser M, Widhalm G, Sax C, Marosi C, Seliger C, Kumthekar PU, Leukel P, Jachnik B, Bogdahn U, Vollmann A, Hau P, Chung SA, Luk PP, Shen H, Decollogne S, Day BW, Grimm SA, Stringer BW, Hogg PJ, Dilda PJ, McDonald KL, Cernea DR, Pruteanu P, Todor N, Florian S, Bogdan V, Cercea C, Chandler J, Leibetseder A, Ackerl M, Flechl B, Sax C, Widhalm G, Dieckmann K, Preusser M, Marosi C, Torres-Martin M, Pena-Granero C, Helenowski IB, Isla A, Pinto GR, Custodio AC, Melendez B, Castresana JS, Rey JA, Banissi C, Maubant S, Rancic M, Carpentier AF, Marymont M, Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Kaneva R, Poptodorov G, Mitev V, Gabrovsky N, Rademaker A, Piccirillo SGM, Spiteri I, Sottoriva A, Marko N, Tavare' S, Collins P, Watts C, Fedrigo CA, Da Rocha AB, Stalpers LJA, Wagner L, Baumert BG, Slotman B, Peters GJ, Sminia P, Fernandez M, Gawrisch VJ, Ruttgers M, Jachnik B, Proescholdt M, Bogdahn U, Stell B, Vollmann-Zwerenz A, Hau P, Trevisan E, Magistrello M, Bertero L, Bosa C, Greco Crasto S, Garbossa D, Lolli I, Ruda R, Raizer J, Soffietti R, Ichikawa T, Kurozumi K, Onishi M, Ishida J, Shimazu Y, Fujii K, Inoue S, Chiocca EA, Kaur B, Kumthekar PU, Date I, Dictus C, Friauf S, Valous NA, Muerle B, Unterberg AW, Herold-Mende CC, Caroli M, Di Dristofori A, Lucarella F, Grimm S, Menghetti C, Lanfranchi G, Gaini SM, Duerinck J, Clement P, Bouttens F, Neyns B, D'Hondt L, Gennigens C, Staelens Y, Jacobs DI, Joosens E, Van Fraeyenhove F, Rogiers A, Darlix A, Baumann C, Lorgis V, Blonski M, Chauffert B, Zouaoui S, Beauchesne P, Stell BV, Taillandier L, Vaccaro V, Pace A, Vidiri A, Vari S, Telera S, Giannarelli D, Russillo M, Anelli V, Carapella CM, Rademaker A, Fabi A, Florian SI, Soritau O, Neagoe I, Abrudan C, Tomuleasa C, Cernea D, Petrescu M, Baritchii A, Florian SI, Chandler J, Abrudan C, Baritchii A, Fornara O, Mirza S, Khan Z, Odeberg J, Stragliotto G, Butler L, Soderberg-Naucler C, Soderberg Naucler C, Marymont MH, Stragliotto G, Peredo I, Rahbar A, Lilja A, Taher C, Orrego A, Wolmer Solberg N, Brandes AA, Depenni R, Marcello N, Helenowski IB, Valentini A, Faedi M, Urbini B, Crisi G, Franceschi E, Poggi R, Baruzzi A, Berghauser Pont LME, Kloezeman JJ, French PJ, Wagner L, Dirven CMF, Lamfers MLM, Leenstra SL, Stragliotto G, Bartek J, Hylin S, Peredo I, Rahbar A, Soderberg Naucler C, Dahlrot RH, Raizer JJ, Kristensen BW, Hjelmborg JVB, Herrstedt J, Hansen S, Nittby HC, Persson BRR, Ceberg C, Widegren B, Salford LG, Poulsen HS, Claudel G, Grunnet K, Michaelsen SR, Broholm H, Christensen IJ, Tinchon A, Oberndorfer S, Marosi C, Ruda R, Sax C, Calabek B, Muller C, Grisold W, Bouwens T, Trouw L, Heijsman D, Kremer A, van der Spek P, Dirven C, Lamfers M, Al-Khawaja H, Pollanz S, Colmar K, Tinchon A, Calabek B, Oberndorfer S, Pohnl R, Grisold W, Hong Y, Ko K, Lee E, De Groot M, Choenni EP, Garat E, Sizoo EM, Uitdehaag B, Buter J, Van Linde ME, Postma TJ, Taphoorn MJB, Heimans JJ, Reijneveld JC, Bertero L, Bosa C, Beauchesne P, Trevisan E, Tarenzi L, Garbossa D, Mantovani C, Soffietti R, Ruda R, Lotsch D, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Hassani K, Petznek H, Grusch M, Berger W, Kaloshi G, Spahiu O, Djamandi P, Djamandi P, Ruka M, Haxhihyseni E, Bushati T, Bethune B, Petrela M, Tabatabai G, Felsberg J, Sabel M, Hofer S, Westphal M, Weller M, Reifenberger G, Wertz M, Padovani L, Nguyen-Thi P, Bequet-Boucard C, Barrie M, Matta M, Muracciole X, Chinot O, Timmer M, Rohn G, Goldbrunner R, Thon N, Kreth F, Di Patrizio P, Simon M, Westphal M, Schackert G, Nikkhah G, Tatagiba M, Hentschel B, Weller M, Tonn J, Smrdel U, Fack F, Taillandier L, Zheng L, Frezza C, Keunen O, Kalna G, Nazarov P, Gottlieb E, Niclou SP, Bjerkvig R, Radic J, Murgic J, Sizoo EM, Maric Brozic J, Jazvic M, Soldic Z, Bolanca A, Raizer J, Grimm S, Levy R, Muro K, Rosenow J, Chandler J, Taphoorn MJB, Bredel M, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Cechakova E, Trojanec R, Kneblova M, Hajduch M, Ehrmann J, Uitdehaag B, Naskhletashvili DR, Gorbounova V, Bychkov M, Bekyashev A, Karakhan V, Aloshin V, Fu R, Moskvina E, Gaziel TB, Poulsen HS, Heimans JJ, Muhic A, Rahbar A, Peredo I, Wolmer Solberg N, Taher C, Dzabic M, Xu X, Skarman P, Tammik C, Stragliotto G, Deliens L, Soderberg-Naucler C, Ahluwalia MS, hashemi-Sadraei N, Barnett GH, Fabbro M, Laigre M, Langlois C, Castan F, Bauchet L, Duffau H, Reijneveld JC, Bonafe A, Spoor JKH, Khorami K, Kloezeman J, Balvers R, Dirven C, Lamfers M, Leenstra S, Spoor JKH, van der Kaaij M, Pasman HW, Kloezeman J, Geurtjens M, Dirven C, Lamfers M, Leenstra S, Trister AD, Neal ML, Cloke T, Baldock AL, Ahn S, Rampling RP, Mrugala MM, Rockhill JK, Rockne R, Swanson KR, Swanson KR, Rockne R, Hawkins-Daarud A, Corwin D, Neal ML, Rockhill JK, James A, Mrugala MM, Rostomily R, Alvord EC, D'Alessandro G, Catalano M, Cipriani R, Chece G, Limatola C, Graham K, Williamson A, Mulholland P, Lamb C, James A, Clark B, Chalmers A, de Kunder SL, Postma AA, Huysentruyt CJR, Dings J, ter Laak-Poort MP, Seystahl K, Peoples S, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A, Janz C, Buhl RM, Jiang T, Darlix A, Al-Salihi O, Virion J, Zouaoui S, Rigau V, Tretarre B, Mandonnet E, Pinelli C, Duffau H, Taillandier L, Bauchet L, Ng H, Twelves C, Yang L, Pang JCS, Roelcke U, Nowosielski M, Bertero L, Crippa F, Hofer S, Bruehlmeier M, Remonda L, Soffietti R, Halford S, Wyss M, Reyes-Botero G, Fiorelli M, Mokhtari K, Delattre J, Laigle-Donadey F, Amelio D, Lorentini S, Giri MG, Meliado G, McGuigan L, Fellin F, Gargano G, Ricciardi GK, Pioli F, Schwarz M, Amichetti M, Ribba B, Kaloshi G, Peyre M, Ricard D, Ritchie J, Tod M, Cartalat-Carel S, Delattre J, Honnorat J, Grenier E, Ducray F, Bastin F, Pirotte B, Bouquey D, Roger T, Sing-Jasuja H, Riva M, Raneri F, Pessina F, Casarotti A, Comi A, Fava E, Papagno C, Bello L, Blonski M, Pallud J, Schumacher T, Goze C, Mandonnet E, Beauchesne P, Baron M, Fontaine D, Darlix A, Duffau H, Taillandier L, Sinclair G, Hylin S, Sahm F, Nordstrom L, Stragliotto G, Mucha-Malecka A, Glinski B, Malecki K, Ahluwalia MS, Robles Irizarry L, Hashemi Sadraei N, Stevens G, Barnett GH, von Deimling A, Mucha-Malecka A, Glinski B, Malecki K, Jarosz M, Dymek P, Chrostowska A, Hetnal M, Miwa T, Oi S, Nonaka Y, Wick W, Sasaki H, Adachi J, Suzuki T, Yanagisawa T, Mishima K, Fukuoka K, Koga T, Matsutani M, Nishikawa R, Burger MC, Platten M, Brucker DP, Baumgarten P, Ronellenfitsch MW, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Mittelbronn M, Steinbach JP, Walker DA, Ardon H, Collier J, Kennedy C, Grundy R, Wilne S, Lakhanpaul M, Baker M, Trusler J, Linsell S, Dudley J, Kieffer V, Ewelt C, Dellatolas G, Chevignard M, Puget S, Dhermain F, Grill J, Dufour C, Messina R, Zambuto M, Calace A, De Tommasi A, Gunes D, Malova JV, Peyrl A, Sauermann R, Chocholous M, Azizi AA, Prucker C, Jaeger W, Hoeferl M, Slavc I, Pollo B, Wolfer J, Maderna E, Vuono R, Farinotti M, Massimino M, Finocchiaro G, Valentini L, Aurtenetxe O, Urberuaga A, Lopez J, Gaafar A, De Vleeschouwer S, Navajas A, Perez Bovet J, Kusak M, Martinez Moreno N, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Yachi K, Kurihara J, Fukushima T, Stummer W, Watanabe T, Yoshino A, Katayama Y, Nishimoto H, Ghasimi S, Haapasalo H, Eray M, Korhonen K, Brannstrom T, Hedman H, Wick W, Andersson U, Miyatake S, Kawabata S, Hiramatsu R, Hirota Y, Kuroiwa T, Ono K, Sugio H, Ito T, Ozaki Y, Meisner C, Sato K, Oikawa M, Daniel R, Tuleasca C, Negretti L, Magaddino V, Levivier M, Pfister C, Pfrommer H, Tatagiba MS, Hentschel B, Roser F, Linsler S, Reuss D, Urbschat S, Klotz M, Ketter R, Oertel J, Ketter R, Linsler S, Kramer D, Platten M, Driess C, Lerner C, Oertel J, Urbschat S, Williamson A, Smith S, Clark B, Chalmers A, James A, Saini SS, Sabel M, Hall G, Davis C, Jang W, Jung S, Jung T, Moon K, Kim I, Carrabba G, Conte V, Riva M, Koeppen S, Caroli M, Artoni A, Martinelli I, Gaini SM, Martinez Moreno NE, Kusak ME, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Megyesi JF, Ketter R, Macdonald D, Chaudhary N, Weber DC, Li J, Miller R, Villa S, Anacak Y, Poortmans P, Baumert B, Pica A, Simon M, Ozyigit G, Preusser M, Torres-Martin M, Lassaletta L, Pena-Granero C, de Campos JM, Gutierrez M, Castresana JS, Rey JA, Suki D, Reifenberger G, Sivaganean A, Rao G, Rhines LD, Caffo M, Barresi V, Cacciola F, Giugno A, Passalacqua M, Alafaci C, Caruso G, Weller M, Tomasello F, Widhalm G, Kiesel B, Novak K, Wohrer A, Matula C, Prayer D, Marosi C, Preusser M, Knosp E, Gallego Perez-Larraya J, Wolfsberger S, De Campos JM, Kusak ME, Aguirre DT, Ordonez C, Fortes J, Chamberlain MC, Ellithy MAM, Ghali RR, Abdelhakim KN, Sampron N, Abdelmonem A, Elwakil LM, Heesters MAAM, van der Weide HL, Bolt RA, Enting RH, Glaudemans AWMJ, Bijl HP, van Dijk JMC, Langendijk JA, Matheu A, Chmielowska E, Lewandowska K, Studzinski M, Olejniczak M, Kwiatkowski M, Subira D, Illan J, Serrano C, Simo M, Pardo J, Ayuso A, Martinez-Garcia M, Gil-Bazo I, Sepulveda JM, Hinojo C, Bruna J, Chmielowska E, Krause A, Swiezynski M, Lewandowska K, Olejniczak M, Paris S, Chung C, Menard C, Stevens C, Laperriere N, Millar B, Bernstein M, Zadeh G, Mason W, Brade A, Kim J, Tejada-Solis S, Pardo J, Bruna J, Gomez L, Subira D, Fernandez A, Serrano C, Gonzalez F, Velasco R, Gil M, Perez-Carrion R, Diez-Valle R, Levivier M, Magaddino V, Negretti L, Tuleasca C, Moeckli R, Auslands K, Liepa Z, Apskalne D, Ozols R, Ogino A, Lopez de Munain A, Hirai T, Fukushima T, Serizawa T, Yachi K, Ohta T, Watanabe T, Yoshino A, Hirayama T, Katayama Y, Slavc I, Manterola L, Chocholous M, Czech T, Peyrl A, Dorfer C, Prucker C, Haberler C, Woehrer A, Azizi A, Antoni D, Clavier J, Alonso MM, Noel G, Antoni D, Clavier J, Noel G, Pardo J, Cuadrado ML, Fernandez C, Broemme JO, Schucht P, Beck J, Weiler M, Abu-Isa J, Kottke R, Malthaner M, Schmidthalter D, Aebersold DM, Pica A, Carpentier A, Peignaux K, Bourgeois H, Fauchon F, Blaes J, Prevost J, Azria D, Toulemonde A, Lortholary A, Bonneterre J, Hennequin C, Du Four S, Wilgenhof S, Neyns B, Lam T, Sahm F, Wong F, Sze W, Tung S, Calabek B, Pollanz S, Surbock B, DeSantis M, Pohnl R, Ammerer H, Sherif C, Pusch S, Grisold W, Hanssens P, Beute G, Karlsson B, Naskhletashvili DR, Gorbounova V, Bychkov M, Bekyashev A, Karakhan V, Aloshin V, Jugold M, Moskvina E, Rudnicka H, Niwinska A, Murawska M, Save A, Baehring JM, Ghali RR, Basiuony ME, Elleithy MA, Martinez-Garcia M, Kempf T, Momprade E, Alameda F, Capellades J, Ruiz I, Vivanco RM, Manero RM, Foro P, Conesa G, Albanell J, Di Stefano A, Weller M, Berzero G, Vitali P, Bastianello S, Giometto B, Salmaggi A, Marchioni E, Velasco R, Simo M, Santos C, Gil M, Platten M, Salazar R, Galan M, Palmero R, Ale A, Bruna J, Lee DZJ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, Wick W, Yevtushenko S, Goncharova Y, Filimonov D, Symonian V, Viaccoz A, Karantoni E, Ducray F, Picard G, Cavillon G, Rogemond V, McDonald KL, Antoine J, Delattre J, Honnorat J, Koekkoek JAF, Sizoo EM, Postma TJ, Heimans JJ, Pasman RW, Deliens L, Taphoorn MJB, Rapkins R, Reijneveld JC, Muller C, Claudel G, Garat E, Beauchesne P, Hassani K, Labrude M, Taillandier L, Logan J, Hurwitz V, Zhau L, Bhangoo R, Ashkan K, Brazil L, Beaney R, Thier K, Calabek B, Tinchon A, Grisold W, Oberndorfer S, Kallio M, Hitchins M, Kaipio M, Baraniskin A, Kuhnhenn J, Schlegel U, Schmiegel W, hahn S, Schroers R, Mrugala MM, Crew LK, Mishima K, Agnihotri S, Suzuki T, Adachi J, Koga T, Fukuoka K, Yanagisawa T, Fujimaki T, Nishikawa R, Gonzalez-Aguilar A, Boisselier B, Polivka M, Gajadhar A, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Vital A, Mokhtari K, Hoang-Xuan K, Sommer B, Grummich P, Hamer HM, Gorlia T, Blumcke I, Coras R, Buchfelder M, Roessler K, Rozumenko VD, Rozumenko AV, Brell M, Roldan P, Gonzalez E, Ibanez J, Margison G, Ibanez J, Brell M, Tomas M, Roldan P, Guibelalde M, Tavera A, Salinas J, Van Geemen K, Klein M, Zwinderman AH, Aldape K, Hillebrand A, Stam CJ, Vandertop WP, De Witt Hamer PC, Senft C, Gessler F, Mittelbronn M, Dutzmann S, Franz K, Hattingen E, Hawkins C, Seifert V, Ngoga DG, Tennant D, Williams A, Cruickshank G, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Hegi M, Conte V, Caroli M, Gaini SM, Oppido P, Carapella C, Pompili A, Vidiri A, Pace A, Shinoda J, Miwa K, Guha A, Yonezawa S, Aki T, Asano Y, Ito T, Yokoyama K, Yamada M, Yamada J, Ceberg C, Jonsson B, Prezado Y, Simo M, Nittby H, Grafstrom G, Stromblad S, Elleaume H, Baldetorp B, Salford LG, Strand S, Hundsberger T, Brugge D, Weder P, Macia M, Weber J, Plasswilm L, Lopci E, Clerici E, Catalano M, Rodari M, Morenghi E, Mancosu P, Navarria P, Scorsetti M, Plans G, Chiti A, Fernandez M, Setua S, Watts C, Welland M, Martinez Moreno NE, Kusak ME, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Majos C, Narayan RS, Renwarin L, van den Berg J, Franken NAP, Stalpers LJA, Baumert BG, Sminia P, Mucha-Malecka A, Sladowska A, Malecki K, Gil M, Glinski B, Kisielewicz K, Torabi Nami M, Hejazi Farahmand S, Mohammadzadeh F, Shao C, Wu M, Xia Y, Chen F, Chen Z, Izquierdo C, Miyatake S, Yoritsune E, Furuse M, Miyata T, Nonoguchi N, Kawabata S, Kuroiwa T, Kuwabara H, Masunaga S, Ono K, Velasco R, Ros T, Horvat Sprah M, Popovic M, Jezersek Novakovic B, Kerrigan SJ, Erridge S, Whittle I, Grant R, Verissimo CS, Molenaar JJ, Bruna J, Meerman J, Puigvert JC, Pont C, Danen EHJ, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E, Marques J, Costa I, Yanagisawa T, Passos J, Azevedo A, Salgado D, Teixeira G, Ferreira I, Guimaraes A, Miranda N, Abecasis M, Bosa C, Magistrello M, Suzuki K, Trevisan E, Morra I, Fiano V, Dealis C, Ruda R, Soffietti R, Mackinnon M, Williamson A, Lamb C, Chalmers A, Fukuoka K, Clark B, James A, Fernandez M, Blanchette M, Tremblay L, Lepage M, Fortin D, Matos Nunes B, Bujor L, Vasconcelos A, Kohga T, Amado A, Monteiro Grillo I, Muggeri AD, Calabrese B, Cerrato S, Cervio A, Diez B, Moser W, Tinchon A, Calabek B, Adachi J, Hitzenberger P, Grisold W, Oberndorfer S, Kusak ME, De Campos JM, Martinez Moreno NE, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Kubben PL, MIshima K, De Campos JM, Vinas D, Kusak ME, Lo Presti A, Montoya J, Matsutani M, Fujimaki T, Nisikawa R, Kuhnhenn J, Pels H, Reiser M, Deckert M, Egerer G, Vogt-Schaden M, Schackert G, Kroschinsky F, Schmidt-Wolf IGH, Schlegel U, Schiff D, Taylor JW, Flanagan E, O'Neill BP, Siegal T, Omuro A, Baehring J, Gonzalez-Aguilar A, Chamberlain M, Nishikawa R, Zach L, Guez D, Grober Y, Last D, Daniels D, Hoffman C, Nissim O, Spiegelmann R, Cohen ZR, Mardor Y, Radbruch A, Kramp L, Wiestler B, Heiland S, Wick W, Bendszus M, Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E, Berghoff AS, Lassmann H, Hoftberger R, Preusser M, Mercurio-Smit S, Padovani L, Colin C, Andre N, Fernandez C, Figarella-Branger D, Ruda R, Bertero L, Trevisan E, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bomprezzi C, Soffietti R, Kunz M, Armbruster L, Thon N, Jansen N, Egensperger R, Eigenbrod S, Lutz J, Fougere la C, Tonn J, Kreth F, Berntsson S, Savitcheva I, Larsson E, Smits A, van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven M, Delattre JY, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang Xuan K, Weller M, Meisner C, Platten M, Simon M, Nikkhah G, Papsdorf K, Sabel M, Braun C, Reifenberger G, Wick W, Kerrigan SJ, Graham C, Stenning S, Thompson LC, Rooney A, Brada M, Grant R, Beauchesne PD, Faure G, Noel G, Schmitt T, Martin L, Jadaud E, Balvers R, Kloezeman JK, Kleijn A, Kremer A, French PJ, Dirven CMF, Leenstra S, Lamfers MLM, Bougnaud S, Golebiewska A, Oudin A, Brons NHC, Bjerkvig R, Niclou SP, Smith SJ, Ward JH, Wilson M, Rahman C, Rose F, Peet A, Macarthur DC, Grundy RG, Rahman R, Cuppini L, Calleri A, Bruzzone M, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Bertolini F, Finocchiaro G, Eoli M, Lang FF, Shinojima N, Gumin J, Takezaki T, Hossain A, Sevim H, Chung L, Wheeler HT, Baxter RC, McDonald KL, Alentorn A, Marie Y, Boisselier B, Carpentier C, Mokhtari K, Capelle L, Hoang-Xuan K, Sanson M, Delattre J, Idbaih A, Lathia J, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Carson C, Naik U, Hjelmeland A, Majumder S, Rich J, Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones DTW, Korshunov A, Tonjes M, Plass C, Jabado N, Pfister SM, Johansson M, Oudin A, Tiemann K, Bernard A, Keunen O, Fack F, Golebiewska A, Stieber D, Wang B, Hedman H, Niclou SP, Alexiou GA, Vartholomatos G, Karamoutsios A, Voulgaris S, Cho W, Patil S, Burzynski S, Mrowczynski E, Grela K, Moeckel S, Meyer K, Bosserhoff A, Spang R, Leukel P, Proescholdt M, Bogdahn U, Vollmann A, Hau P, Nakabayashi H, Shimizu K, Schroeteler J, Reeker R, Suero E, Stummer W, Ewelt C, Campos B, Gal Z, Baader A, Schneider T, Bageritz J, Schmoch T, Mogler C, Goidts V, Unterberg A, Herold-Mende CC, Hagemann C, Kessler AF, Fett S, Hofmann L, Monoranu CM, Al-Jomah N, Polat B, Patel R, Ernestus RI, Vince GH, Busek P, Balaziova E, Hilser M, Vomelova I, Fejfarova E, Sromova L, Sedo A, Kessler AF, Hagemann C, Hofmann L, Patel R, Linsenmann T, Ernestus RI, Vince GH, Sooman L, Ekman S, Bergqvist M, Gullbo J, Bergstrom S, Johansson M, Wu X, Blomquist E, Lennartsson J, Shimazu Y, Levallet G, Planchard G, Duguet AE, Emery E, Guillamo J, Geffrelot J, Zalcman G, Lechapt-Zalcman E, Sjostrom S, Ghasimi S, Broholm H, Brannstrom T, Johansen C, Collatz-Laier H, Henriksson R, Andersson U, Melin B, Kuratsu J, Nakamura H, Makino K, ducray F, meyronet D, Cartalat-Carel S, Guyotat J, Jouanneau E, Frappaz D, d'Hombres A, Sunyach M, Bauchet L, Honnorat J, Jaramillo E, Vargas C, Tze-Chun T, Huang S, Liu J, Hamdan A, Mitchell P, Flechl B, Ackerl M, Sax C, Oberndorfer S, Calabek B, Sizoo E, Reijenfeld J, Crevenna R, Preusser M, Marosi C, Rozumenko V, Khoroshun A, Rozumenko A, Fischbach P, Haquet A, Dutilleux A, Bracke J, Al Bassir M, Denoel C, Pace A, Villani V, Grattarola C, Di Napoli L, Maschio M, Benincasa D, Zucchella C, Burdukova YA, Vlasova EY, Gniteeva LN, Alekseeva OS, Voronin NA, Andreeva EV, Gorbatykh SV, Pavlova EV, Popov VE, Stroganova TA, Satoer DD, Kloet A, Vincent AJPE, Dirven CMF, Visch-Brink EG, Ungureanu G, Alexandra C, Ioana I, Paul M, Rares M, Oana M, Ioan Stefan F, Abdel Karim K, Abdel Wahab MM, Ezz LR, Abdel Raouf S, Shevtsov MA, Pozdnyakov AV, Kim AV, Samochernych KA, Guzhova IV, Romanova IV, Khachatryan WA, Margulis BA, Kleijn A, Kloezeman JJ, Treffers-Westerlaken EJ, Leenstra S, Dirven CMF, Debets R, Lamfers MML, Chirasani SR, Leukel P, Gronwald W, Gottfried E, Stadler K, Bogdahn U, Hau P, Kreutz M, Grauer OM, Persson BR, Engstrom P, Grafstrom G, Baureus Koch C, Widegren B, Salford LG, Gramatzki D, Peipp M, Staudinger M, Weller M, Hill LJ, Hossain-Ibrahim K, Logan A, Cruickshank GS, Pellegatta S, Eoli M, Antozzi C, Frigerio S, Cantini G, Bruzzone M, Anghileri E, Pollo B, Parati E, Finocchiaro G, Stragliotto G, Holm S, Adamson L, Giraud G, Hansson M, Henter J, Martinez-Garcia M, Villalonga R, Martinez-Soler F, Gimenez-Bonafe P, Acebes JJ, Casanovas O, Gil M, Tortosa A, Vinals F, Sander P, Leukel P, Vollmann-Zwerenz A, Jachnik B, Dobner C, Bogdahn U, Kalbitzer H, Hau P, Weissenberger J, Mutlu A, Hensel S, Senft C, Seifert V, Kogel D, Hossain-Ibrahim K, Hill LJ, Logan A, Cruickshank GS, Jung S, Wen M, Pei J, Jang W, Jung T, Kim I, Ishida J, Ichikawa T, Kurozumi K, Inoue S, Maruo T, Onishi M, Fujii K, Shimazu Y, Chiocca A, Date I, Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca E, Kaur B, Date I, Kang S, Sin G, Shim J, Lee S, Huh Y, Kim E, Chang J, Kim S, Hong Y, Kim D, Lefranc F, Verschuere T, De Witte O, Van Gool S, Kiss R, DeVleeschouwer S, Ewelt C, Ardon H, Suero E, Gunes D, Wolfer J, Fischer B, Stummer W, Thorsteinsdottir J, Fu P, Gehrmann M, Multhoff G, Tonn JC, Schichor C, Jachtenberg J, Bakker Schut T, Puppels G, French P, Kros M, Lamfers M, Leenstra S, Costello PC, McDonald W, MacDonald D, Zlatescu M, Megyesi J, Rossetto M, Gallego Perez-Larraya J, Boisselier B, Ciccarino P, Labussiere M, Marie Y, Delattre J, SANSON M, Ilhan-Mutlu A, Wohrer A, Berghoff AS, Widhalm G, Marosi C, Wagner L, Preusser M, Di Stefano A, Gallego Perez-Larraya J, Ducray F, Boisselier B, Labussiere M, Paris S, Cheneau C, Delattre J, Sanson M, Lonnqvist F, Gaillard PJ, Gladdines W, Boogerd W, van Tellingen O, Milojkovic Kerklaan B, Schellens JHM, Brandsma D, Denicolai E, Baeza-Kallee N, Tchoghandjian A, Beclin C, Figarella-Branger D, Rahman CV, Smith SJ, Morgan PS, Langmack KA, Macarthur DC, Rose FR, Shakesheff KM, Grundy RG, Rahman R, Nowosielski M, DiFranco MD, Putzer D, Seiz M, Jacobs AH, Stockhammer G, Hutterer M, Okada M, Shishido H, Hatakeyama T, Shinomiya A, Miyake K, Kawai N, Tamiya T, Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T, Alexiou GA, Tsiouris S, Papadopoulos A, Al-Bokharhli J, Kyritsis AP, Voulgaris S, Fotopoulos AD, Roelcke U, Boxheimer L, Fathi AR, Schwyzer L, Ortega M, Berberat J, Grobholz R, Remonda L, Oikawa M, Sato K, Ito T, Sugio H, Ozaki Y, Nakamura H, Schwyzer L, Berberat J, Boxheimer L, Remonda L, Roelcke U, Kozic D, Njagulj V, Gacesa JP, Prvulovic N, Semnic R, Basmaci M, Hasturk AE, Hasturk AE, Basmaci M, Bahr O, Weise L, Harter PN, Weiss C, Starzetz T, Steinbach JP, Mittelbronn M, Hattingen E, Price SJ, Young AMH, Thomas OM, Mohsen LA, Frary AJ, Lupson VC, McLean MA, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Grefkes C, Goldbrunner R, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Grefkes C, Goldbrunner R, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Rehme A, Grefkes C, Goldbrunner R, Grech-Sollars M, Saunders DE, Phipps KP, Clayden JD, Clark CA, Schwyzer L, Berberat J, Boxheimer L, Remonda L, Roelcke U, Booth TC, Larkin T, Yuan Y, Kettunen M, Markowetz F, Scoffings D, Jefferies S, Brindle KM, Pica A, Hauf M, Slotboom J, Beck J, Schucht P, Aebersold DM, Wiest R, Pace A, Marzi S, Fabi A, Carapella CM, Giovinazzo G, Marucci L, Anelli V, Vidiri A, Riva M, Castellano A, Raneri F, Pessina F, Fava E, Falini A, Bello L, Gahramanov S, Muldoon LL, Varallyay CG, Li X, Kraemer DF, Fu R, Hamilton BE, Rooney WD, Neuwelt EA, Hawkins-Daarud A, Rockne R, Muzi M, Patridge S, Kinahan P, Swanson KR, Radbruch A, Fladt J, Wiestler B, Baumer P, Heiland S, Wick W, Bendszus M, Lwin M, Al-Salihi O, Sharpe G, Izmailov TR, Panshin GA, Datsenko PV, Kavsan VM, Balynska EV, Chernolovskaya EL, Zenkova MA, Buhl RM, Janz C, Gomez Gallego J, Albanna W, Rashidi A, Schmiegelow P, Buhl RM, Alexiou GA, Vartholomatos G, Karamoutsios A, Voulgaris S, Shen D, Wang J, Qiu Z, Chen F, Chen Z, Miwa K, Shinoda J, Ito T, Yokoyama K, Yamada M, Yamada J, Yano H, Iwama T, Brokinkel B, Schober O, Heindel W, Hargus G, Paulus W, Stummer W, Woelfer J, Aoki T, Arakawa Y, Ueba T, Miyatake S, Nozaki K, Taki W, Tsukahara T, Miyamoto S, Matsutani M, Satou K, Ito T, Takanashi M, Oikawa M, Ozaki Y, Sugio H, Nakamura H. Abstracts of the 10th Congress of the European Association of NeuroOncology. Marseille, France. September 6-9, 2012. Neuro Oncol 2012; 14 Suppl 3:iii1-109. [PMID: 22977921 DOI: 10.1093/neuonc/nos183] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
131
|
Guergueltcheva V, Azmanov DN, Angelicheva D, Smith KR, Chamova T, Florez L, Bynevelt M, Nguyen T, Cherninkova S, Bojinova V, Kaprelyan A, Angelova L, Morar B, Chandler D, Kaneva R, Bahlo M, Tournev I, Kalaydjieva L. Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1. Am J Hum Genet 2012; 91:553-64. [PMID: 22901947 DOI: 10.1016/j.ajhg.2012.07.019] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 06/19/2012] [Accepted: 07/18/2012] [Indexed: 01/19/2023] Open
Abstract
Autosomal-recessive congenital cerebellar ataxia was identified in Roma patients originating from a small subisolate with a known strong founder effect. Patients presented with global developmental delay, moderate to severe stance and gait ataxia, dysarthria, mild dysdiadochokinesia, dysmetria and tremors, intellectual deficit, and mild pyramidal signs. Brain imaging revealed progressive generalized cerebellar atrophy, and inferior vermian hypoplasia and/or a constitutionally small brain were observed in some patients. Exome sequencing, used for linkage analysis on extracted SNP genotypes and for mutation detection, identified two novel (i.e., not found in any database) variants located 7 bp apart within a unique 6q24 linkage region. Both mutations cosegregated with the disease in five affected families, in which all ten patients were homozygous. The mutated gene, GRM1, encodes metabotropic glutamate receptor mGluR1, which is highly expressed in cerebellar Purkinje cells and plays an important role in cerebellar development and synaptic plasticity. The two mutations affect a gene region critical for alternative splicing and the generation of receptor isoforms; they are a 3 bp exon 8 deletion and an intron 8 splicing mutation (c.2652_2654del and c.2660+2T>G, respectively [RefSeq accession number NM_000838.3]). The functional impact of the deletion is unclear and is overshadowed by the splicing defect. Although ataxia lymphoblastoid cell lines expressed GRM1 at levels comparable to those of control cells, the aberrant transcripts skipped exon 8 or ended in intron 8 and encoded various species of nonfunctional receptors either lacking the transmembrane domain and containing abnormal intracellular tails or completely missing the tail. The study implicates mGluR1 in human hereditary ataxia. It also illustrates the potential of the Roma founder populations for mutation identification by exome sequencing.
Collapse
|
132
|
Kamenarova K, Cherninkova S, Romero Durán M, Prescott D, Valdés Sánchez ML, Mitev V, Kremensky I, Kaneva R, Bhattacharya SS, Tournev I, Chakarova C. A novel locus for autosomal dominant cone-rod dystrophy maps to chromosome 10q. Eur J Hum Genet 2012; 21:338-42. [PMID: 22929024 DOI: 10.1038/ejhg.2012.158] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Here we report recruitment of a three-generation Romani (Gypsy) family with autosomal dominant cone-rod dystrophy (adCORD). Involvement of known adCORD genes was excluded by microsatellite (STR) genotyping and linkage analysis. Subsequently, two independent total-genome scans using STR markers and single-nucleotide polymorphisms (SNPs) were performed. Haplotype analysis revealed a single 6.7-Mb novel locus between markers D10S1757 and D10S1782 linked to the disease phenotype on chromosome 10q26. Linkage analysis gave a maximum LOD score of 3.31 for five fully informative STR markers within the linked interval corresponding to the expected maximum in the family. Multipoint linkage analysis of SNP genotypes yielded a maximum parametric linkage score of 2.71 with markers located in the same chromosomal interval. There is no previously mapped CORD locus in this interval, and therefore the data reported here is novel and likely to identify a new gene that may eventually contribute to new knowledge on the pathogenesis of this condition. Sequencing of several candidate genes within the mapped interval led to negative findings in terms of the underlying molecular pathogenesis of the disease in the family. Analysis by comparative genomic hybridization excluded large chromosomal aberrations as causative of adCORD in the pedigree.
Collapse
Affiliation(s)
- Kunka Kamenarova
- Department of Cellular Therapy and Regenerative Medicine, CSIC-CABIMER, Seville, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
133
|
Dourmishev L, Kamenarska Z, Hristova M, Dodova R, Kaneva R, Mitev V. Association of TNF-α polymorphisms with adult dermatomyositis and systemic lupus erythematosus in Bulgarian patients. Int J Dermatol 2012; 51:1467-73. [DOI: 10.1111/j.1365-4632.2012.05522.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
134
|
Dacheva D, Dodova R, Mitkova A, Vlahova A, Dikov T, Valev S, Timcheva C, Christova S, Mitev V, Kaneva R. 546 Mutation Screening of BRCA2 Exon 11 and Exon 17 in Bulgarian Breast Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71205-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
135
|
Kachakova D, Popov E, Mitkova A, Beltcheva O, Vlahova A, Dikov T, Christova S, Slavov C, Mitev V, Kaneva R. 520 Promoter Hypermethylation of HIST1H4K and RASSF2 in Urine From Prostate Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71182-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
136
|
Pierini S, Jordanov S, Mitkova A, Chalakov I, Kaneva R, Mitev V, Melnicharov M, Goranova T. 527 CDKN2a Promoter Hypermethylation is Associated With Environmental Risk Factors in Patients With Laryngeal Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71187-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
137
|
Todorova T, Jordanov S, Stancheva G, Mitkova A, Chalakov I, Kaneva R, Mitev V, Melnicharov M, Goranova T. 512 Genetic Aberrations in CDKN2a and TP53 Genes in Patients With Laryngeal Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71176-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
138
|
Marinova D, Stancheva G, Kachakova D, Mitkova A, Slavova Y, Maksimov V, Kaneva R, Mitev V. 627 Gene Expression of EGFR and Mina53 in Different Histological Subtypes of Lung Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71276-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
139
|
Bichev S, Marinova D, Slavova Y, Kaneva R, Savov A. 1146 Assessment of Frequency of the EGFR Mutations According to the Histological Type and Sex of Bulgarian Patients with NSCLC. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71742-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
140
|
Alexeeva E, Kozlova A, Valieva S, Bzarova T, Chomahizde A, Isaeva K, Denisova R, Slepcova T, Starkova A, Amirdzhanova V, Alexandrova E, Avdeeva A, Novikov A, Panasyuk E, Cherkasova M, Klimova N, Nasonov E, Aggarwal A, Sharma A, Bhatnagar A, Dubula T, Mody GM, Abdel-Wahab N, Tayseer Khedr S, Rashad E, Alkady E, Mosad, Owino L, Ubeer A, Pan Z, Liu X, Xu J, Zhang Y, Omurzakova NA, Volkava M, Kundzer A, Generalov I, Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA, Conn DL, Smith EA, Gersuk VH, Nepom GT, Moreland LW, Furst DE, Thompson SD, Jonas BL, Michael Holers V, Glass DN, Chen PP, Louis Bridges S, Weinblatt ME, Paulus HE, Tsao BP, Umar S, Ahmad S, Kant Katiyar C, Khan HA, Munoz A, Martinez R, Rodriguez S, Luis Marenco J, Lu Z, Guo-chun W, Shah D, Bhatnagar A, Wanchu A, Sherif Suliman YA, Budhoo A, Mody GM, Hristova M, Kamenarska Z, Dourmishev L, Baleva M, Kaneva R, Savov A, Retamozo S, Diaz-Lagares C, Brito-Zeron P, Gomez ME, Bosch X, Bove A, Forns X, Yague J, Ramos-Casals M, Chen Z, Li XM, Wang GS, Qian L, Li XP, Zu N, Zhao H, Xu B, Li HY, Xiang Q, Wang GC, Mazur-Nicorici L, Mazur M, Crib L, Ding H, Chen S, Ye S, Fedorenko E, Lukina G, Sigidin Y, Hammam N, Orabi H, Lue TF, Goel R, Danda D, Eapen C, Mathew J, Kumar S. Abstracts from EIR School ES01-ES25. Rheumatology (Oxford) 2012. [DOI: 10.1093/rheumatology/ker439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
141
|
Leu C, de Kovel CGF, Zara F, Striano P, Pezzella M, Robbiano A, Bianchi A, Bisulli F, Coppola A, Giallonardo AT, Beccaria F, Trenité DKN, Lindhout D, Gaus V, Schmitz B, Janz D, Weber YG, Becker F, Lerche H, Kleefuss-Lie AA, Hallman K, Kunz WS, Elger CE, Muhle H, Stephani U, Møller RS, Hjalgrim H, Mullen S, Scheffer IE, Berkovic SF, Everett KV, Gardiner MR, Marini C, Guerrini R, Lehesjoki AE, Siren A, Nabbout R, Baulac S, Leguern E, Serratosa JM, Rosenow F, Feucht M, Unterberger I, Covanis A, Suls A, Weckhuysen S, Kaneva R, Caglayan H, Turkdogan D, Baykan B, Bebek N, Ozbek U, Hempelmann A, Schulz H, Rüschendorf F, Trucks H, Nürnberg P, Avanzini G, Koeleman BPC, Sander T. Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies. Epilepsia 2012; 53:308-18. [PMID: 22242659 DOI: 10.1111/j.1528-1167.2011.03379.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
PURPOSE Genetic generalized epilepsies (GGEs) have a lifetime prevalence of 0.3% with heritability estimates of 80%. A considerable proportion of families with siblings affected by GGEs presumably display an oligogenic inheritance. The present genome-wide linkage meta-analysis aimed to map: (1) susceptibility loci shared by a broad spectrum of GGEs, and (2) seizure type-related genetic factors preferentially predisposing to either typical absence or myoclonic seizures, respectively. METHODS Meta-analysis of three genome-wide linkage datasets was carried out in 379 GGE-multiplex families of European ancestry including 982 relatives with GGEs. To dissect out seizure type-related susceptibility genes, two family subgroups were stratified comprising 235 families with predominantly genetic absence epilepsies (GAEs) and 118 families with an aggregation of juvenile myoclonic epilepsy (JME). To map shared and seizure type-related susceptibility loci, both nonparametric loci (NPL) and parametric linkage analyses were performed for a broad trait model (GGEs) in the entire set of GGE-multiplex families and a narrow trait model (typical absence or myoclonic seizures) in the subgroups of JME and GAE families. KEY FINDINGS For the entire set of 379 GGE-multiplex families, linkage analysis revealed six loci achieving suggestive evidence for linkage at 1p36.22, 3p14.2, 5q34, 13q12.12, 13q31.3, and 19q13.42. The linkage finding at 5q34 was consistently supported by both NPL and parametric linkage results across all three family groups. A genome-wide significant nonparametric logarithm of odds score of 3.43 was obtained at 2q34 in 118 JME families. Significant parametric linkage to 13q31.3 was found in 235 GAE families assuming recessive inheritance (heterogeneity logarithm of odds = 5.02). SIGNIFICANCE Our linkage results support an oligogenic predisposition of familial GGE syndromes. The genetic risk factor at 5q34 confers risk to a broad spectrum of familial GGE syndromes, whereas susceptibility loci at 2q34 and 13q31.3 preferentially predispose to myoclonic seizures or absence seizures, respectively. Phenotype- genotype strategies applying narrow trait definitions in phenotypic homogeneous subgroups of families improve the prospects of disentangling the genetic basis of common familial GGE syndromes.
Collapse
|
142
|
Tzveova R, Naydenova G, Tzekova M, Kaneva R, Mitev V. P1.41 THE CYP2J2 G-50T POLYMORPHISM AND MYOCARDIAL INFARCTION IN PATIENTS WITH CARDIOVASCULAR RISK PROFILE. Artery Res 2012. [DOI: 10.1016/j.artres.2012.09.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
143
|
Dourmishev L, Hristova M, Vinkov A, Kamenarska Z, Kaneva R, Baleva M, Mitev V. IL-10 Single Nucleotide Polymorphisms and Lupus-Nephritis. BIOTECHNOL BIOTEC EQ 2012. [DOI: 10.5504/bbeq.2012.0036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
144
|
Hristova M, Dourmishev L, Kamenarska Z, Kaneva R, Vinkov A, Mitev V. Association of tumor necrosis factor α (TNF-α) and interleukin 10 (IL-10) gene polymorphisms in dermatomyositis patients: a pilot study. Acta Dermatovenerol Croat 2012; 20:148-156. [PMID: 23069299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
TNF-α and IL-10 single nucleotide polymorphisms have been implicated in various autoimmune diseases but the results are still quite controversial. This case-control study aimed to investigate the association between six TNF-α and five IL-10 polymorphisms with dermatomyositis. The -857CC and +489GG genotypes showed a weak association with dermatomyositis when the analysis was carried out for the whole cohort but they appeared to be a significant risk factor for the development of dermatomyositis in women. The TNF-α -1031CC genotype was found only among dermatomyositis patients. The TNF-α -1031C/-863C/-857C-308G/+489G haplotype showed a significant association with dermatomyositis in women. The IL-10 -3575TT genotype and T allele showed an association with dermatomyositis. The frequency of the IL-10 -2763CC genotype and C allele was higher among dermatomyositis patents and it was associated with an increased OR. Haplotype analysis showed an association between the IL-10 -3575T/-2763C haplotype and dermatomyositis. In conclusion, our results indicate that both TNF-α and IL-10 polymorphisms are associated with the development of dermatomyositis in Bulgarian patients.
Collapse
Affiliation(s)
- Maria Hristova
- Department of Clinical Laboratory and Clinical Immunology, Sofia Medical University, 28th Diagnostic and Consultative Center, Sofia, Bulgaria
| | | | | | | | | | | |
Collapse
|
145
|
Morar B, Zhelyazkova S, Azmanov DN, Radionova M, Angelicheva D, Guergueltcheva V, Kaneva R, Scheffer IE, Tournev I, Kalaydjieva L, Sander JW. A novel GEFS+ locus on 12p13.33 in a large Roma family. Epilepsy Res 2011; 97:198-207. [DOI: 10.1016/j.eplepsyres.2011.08.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Revised: 08/11/2011] [Accepted: 08/14/2011] [Indexed: 10/17/2022]
|
146
|
Chamova T, Florez L, Guergueltcheva V, Raycheva M, Kaneva R, Lochmüller H, Kalaydjieva L, Tournev I. ANO10 c.1150_1151del is a founder mutation causing autosomal recessive cerebellar ataxia in Roma/Gypsies. J Neurol 2011; 259:906-11. [PMID: 22008874 DOI: 10.1007/s00415-011-6276-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2011] [Revised: 09/29/2011] [Accepted: 10/01/2011] [Indexed: 10/16/2022]
Abstract
A recent report (Vermeer et al. in Am J Hum Genet 87:813-819, 2010) implicated for the first time the ANO10 gene in the genetic basis of autosomal recessive cerebellar ataxias. One of the three described families were Roma/Gypsies from Serbia, where the affected individuals were homozygous for the truncating p.Leu384fs mutation and displayed distinct phenotypic features (Vermeer et al. in Am J Hum Genet 87:813-819, 2010). Based on the history and population genetics of the Roma/Gypsies, we hypothesised that p.Leu384fs could be another founder mutation in this population, whose identification in a larger number of genetically homogeneous patients will contribute to defining the phenotypic spectrum of the disorder. Here, we describe additional patients from neighbouring Bulgaria, outlining invariable ANO10-ataxia features and confirming global intellectual decline as part of the phenotype resulting from complete Anactomin 10 deficit.
Collapse
Affiliation(s)
- Teodora Chamova
- Clinic of Neurology, University Hospital Alexandrovska, Sofia, Bulgaria
| | | | | | | | | | | | | | | |
Collapse
|
147
|
Azmanov DN, Zhelyazkova S, Radionova M, Morar B, Angelicheva D, Zlatareva D, Kaneva R, Tournev I, Kalaydjieva L, Sander JW. Focal epilepsy of probable temporal lobe origin in a Gypsy family showing linkage to a novel locus on 7p21.3. Epilepsy Res 2011; 96:101-8. [DOI: 10.1016/j.eplepsyres.2011.05.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2011] [Revised: 05/03/2011] [Accepted: 05/08/2011] [Indexed: 10/18/2022]
|
148
|
Stefanova M, Jordanov S, Tzveova R, Stancheva G, Mitkova A, Chalakov I, Kaneva R, Mitev V, Goranova T. 8525 POSTER The Prevalence of Microsatellite Instability and Loss of Heterozygosity in Bulgarian Patients With Laryngeal Carcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72167-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
149
|
Stancheva G, Goranova T, Laleva M, Velinov N, Kaneva R, Poptodorov G, Mitev V, Gabrovsky S, Vanev P, Gabrovsky N. 8715 POSTER Comparison of Instruments for Quality of Life Measurement in Bulgarian Patients With Malignant Glial Tumours. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72266-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
150
|
Vlaykova T, Mitkova A, Stancheva G, Kadiyska T, Gulubova M, Yovchev Y, Cirovski G, Chilingirov P, Damyanov D, Kremensky I, Mitev V, Kaneva R. Microsatellite instability and promoter hypermethylation of MLH1 and MSH2 in patients with sporadic colorectal cancer. J BUON 2011; 16:265-273. [PMID: 21766496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
PURPOSE Inactivation of the genes involved in DNA mismatch repair (MMR) is associated with microsatellite instability (MSI) and loss of heterozygosity (LOH). The aim of the current study was to assess the presence of MSI and promoter hypermethylation of MLH1 and MSH2 in Bulgarian PATIENTS WITH SPORADIC COLORECTAL CANCER (CRC) AND TO ANALYZE THEIR POSSIBLE EFFECT ON THE DEVELOPMENT, PROGRESSION AND PROGNOSIS OF THE DISEASE. METHODS We examined MSI in 126 patients with sporadic CRC and the methylation status of the MLH1 and MSH2 promoter regions in the cases with MSI/LOH by using a panel of 5 microsatellite markers (BAT26, D5S346, D18S35, D2S123 and FGA) and methyl-specific PCR (MSP) of bisulfite converted DNA. RESULTS MSI/LOH was found in 36 (28.6%) patients. Among them, 30 were analyzed for promoter hypermethylation of MLH1 and we detected hypermethylation in 15 (50%) of them, whereas promoter hypermethylation of MSH2 was observed only in one case. The presence of MSI/LOH was associated with younger age (p=0.002), more advanced stage (III/IV stage) (p=0.029), lower degree of differentiation (p=0.001), and right-sided tumor localization (p=0.0002), but not with overall survival (log rank, p=0.566). CONCLUSION Our data suggest that sporadic CRCs with MSI/LOH are more aggressive, develop earlier and progress faster to more advanced stage. The most frequent cause of failure of DNA MMR system appeared to be the hypermethylation of CpG islands of the promoter region of MLH1, whereas the methylation of MSH2 was a rare event.
Collapse
Affiliation(s)
- T Vlaykova
- Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, Stara Zagora, Bulgaria.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|